[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23443
1. Higgins PD, Weaver R, Dusenbery KE: Evaluation of bladder dose in intensity-modulated radiation therapy of the prostate. Med Dosim; 2006;31(3):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of bladder dose in intensity-modulated radiation therapy of the prostate.
  • Day-to-day variation in bladder and rectal filling affects prostate location and positioning accuracy.
  • At some institutions, patients are instructed to empty their rectum and fill their bladders prior to treatment in an attempt to standardize the prostate location, displace small bowel out of the radiation field, and move some of the bladder wall away from the high-dose area.
  • Although instructed to come to treatment with a full bladder, it is presumed that there is variability in bladder filling each day of treatment, depending on the amount of fluids consumed and time to treatment.
  • We have reviewed daily bladder volumes on a subset of 5 prostate patients, all of them prescribed to receive 7560 cGy in 42 fractions, and have evaluated the dosimetric consequences of bladder volume changes from full to two-third or one-third filling.
  • Those measurements have been used to help analyze the actual treated bladder volumes for comparison with the treatment plan.
  • Based on our dose-volume model, we estimate that average bladder daily doses were 8-50% higher than predicted by the initial intensity-modulation radiation therapy (IMRT) plan.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905450.001).
  • [ISSN] 0958-3947
  • [Journal-full-title] Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  • [ISO-abbreviation] Med Dosim
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Ritchey M, Ferrer F, Shearer P, Spunt SL: Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2009 Apr;52(4):439-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group.
  • Childhood cancer survivors who have had pelvic or central nervous system surgery or have received alkylator-containing chemotherapy or pelvic radiotherapy as part of their cancer therapy may experience urinary bladder late effects.
  • This article reviews the medical literature on long-term bladder complications in survivors of childhood cancer and outlines the Children's Oncology Group Long-Term Follow-up (COG LTFU) Guidelines related to bladder function.
  • An overview of the treatment of bladder late effects and recommended counseling for survivors with these complications are presented.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Bladder Cancer, Childhood.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [Cites] J Urol. 1982 May;127(5):958-63 [7087000.001]
  • [Cites] Urology. 2005 Apr;65(4):649-53 [15833500.001]
  • [Cites] J Urol. 1988 May;139(5):923-5 [3361664.001]
  • [Cites] Med Pediatr Oncol. 1988;16(6):372-4 [3143903.001]
  • [Cites] J Urol. 1989 Apr;141(4):809-12 [2648027.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1 Suppl 3):2-8 [2649983.001]
  • [Cites] J Urol. 1989 May;141(5):1063-9 [2651710.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):339-44 [2295074.001]
  • [Cites] J Urol. 1990 Jul;144(1):41-3 [2162975.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):614-23 [1548524.001]
  • [Cites] J Urol. 1993 May;149(5):1087-90 [8483218.001]
  • [Cites] Urol Clin North Am. 1993 Aug;20(3):475-83 [8351773.001]
  • [Cites] Acta Oncol. 1993;32(6):679-87 [8260188.001]
  • [Cites] Eur Urol. 1994;25(1):40-2 [7508397.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):1000-3 [7947075.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 15;204(3):1186-92 [7980594.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):532-3 [7844616.001]
  • [Cites] Urology. 2005 Jun;65(6):1226-7 [15922437.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Oct;11(10):797-804 [16182180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):251-7 [15993548.001]
  • [Cites] J Urol. 2006 Jan;175(1):292-6; discussion 296 [16406929.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):476-83 [16421424.001]
  • [Cites] J Urol. 2006 Apr;175(4):1466-70; discussion 1470-1 [16516023.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Aug;18(6):466-73 [16909970.001]
  • [Cites] J Urol. 2006 Nov;176(5):2190-4; discussion 2194-5 [17070290.001]
  • [Cites] Bone Marrow Transplant. 2006 Dec;38(12):825-8 [17133240.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Reprod Med. 2008 May;53(5):360-2 [18567283.001]
  • [Cites] BJU Int. 2003 Aug;92(3):289-92 [12887486.001]
  • [Cites] J Urol. 2000 Jun;163(6):1922-6 [10799230.001]
  • [Cites] J Pediatr Surg. 2000 May;35(5):724-8 [10813335.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 2):1011-5 [10958730.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):563-8, x [10985155.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):899-901 [11081392.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Eur J Pediatr Surg. 2001 Jun;11(3):207-10 [11475121.001]
  • [Cites] Urology. 2002 Jul;60(1):164 [12100953.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):289-91 [14752871.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 2):1649-51; discussion 1651-2 [15371782.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1201-17 [1253131.001]
  • [Cites] Recent Results Cancer Res. 1980;74:270-8 [6777836.001]
  • [Cites] J Urol. 1981 Aug;126(2):205-9 [7196460.001]
  • [Cites] J Cancer Res Clin Oncol. 1981;100(3):311-20 [6792207.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):46-52 [7743237.001]
  • [Cites] Urology. 1995 Dec;46(6):811-5 [7502421.001]
  • [Cites] J Urol. 1996 Jul;156(1):203-5 [8648805.001]
  • [Cites] Radiother Oncol. 1996 May;39(2):167-78 [8735484.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5):571-84 [8893868.001]
  • [Cites] Radiat Res. 1996 Dec;146(6):619-27 [8955711.001]
  • [Cites] Oncology (Williston Park). 1997 Nov;11(11A):25-32 [9430176.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403 [9610789.001]
  • [Cites] Radiat Res. 1999 Apr;151(4):461-7 [10190499.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Mar-Apr;21(2):115-22 [10206457.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):353-9 [10219337.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 2):1197-200 [10458465.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):76-82 [3335893.001]
  • (PMID = 18985721.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA098543-07
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  • [Other-IDs] NLM/ NIHMS183902; NLM/ PMC2917580
  •  go-up   go-down


3. Arikan-Sengul C, Pehlivan Y, Sevinc A, Karakok M, Kalender ME, Camci C: A case of metachronous triple primary urogenital cancer: urinary bladder, prostate, and renal cancer. Onkologie; 2009 Mar;32(3):122-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metachronous triple primary urogenital cancer: urinary bladder, prostate, and renal cancer.
  • BACKGROUND: Multiple primary malignant tumors are rarely seen.
  • We report the case of a heavy smoker with metachronous triple primary cancer occurring in the prostate, kidney and urinary bladder.
  • Computed tomography (CT) showed increased wall thickness of the urinary bladder with an enlarged prostate.
  • After the trans-urothelial resection operation pathological diagnosis was consistent with transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / surgery. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery


Advertisement
4. Lin WY, Hung GU, Tsai SC: A pitfall of FDG-PET image interpretation: accumulation of FDG in the dependent area of the urinary bladder after bladder irrigation--the usefulness of the prone position. Clin Nucl Med; 2005 Sep;30(9):638-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pitfall of FDG-PET image interpretation: accumulation of FDG in the dependent area of the urinary bladder after bladder irrigation--the usefulness of the prone position.
  • In F-18 FDG PET studies, retrograde irrigation of the urinary bladder is usually used to reduce the interference with physiological urinary accumulation of F-18 FDG in patients with possible pelvic lesions.
  • The bladder was irrigated with physiological saline and filled with 200 mL of irrigation fluid through a 3-way balloon catheter inserted before the scan.
  • Tumor invasion or metastasis could not be ruled out.
  • Great caution is required when assessing imaging results to avoid misdiagnosis in patients after bladder irrigation.
  • [MeSH-major] Diagnostic Errors / prevention & control. Extravasation of Diagnostic and Therapeutic Materials / metabolism. Extravasation of Diagnostic and Therapeutic Materials / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Prone Position. Urinary Bladder / metabolism. Urinary Bladder / radionuclide imaging
  • [MeSH-minor] Adult. Artifacts. Female. Humans. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacokinetics. Therapeutic Irrigation / methods. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100493.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Mitrano P, Nogueira MD, Feldner PC Jr, Castro RA, Sartori MG, Nader HB, Girão MJ: Metabolic profile of glycosaminoglycans in bladder and urethra of female rats during and after pregnancy. Int Urogynecol J; 2010 Feb;21(2):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic profile of glycosaminoglycans in bladder and urethra of female rats during and after pregnancy.
  • INTRODUCTION AND HYPOTHESIS: The objective of this study is to evaluate pregnancy's action on glycosaminoglycans (GAGs) profile in bladder and urethra of female adult rats.
  • Significant decrease in total GAGs in bladder was observed at the beginning of pregnancy, with progressive increase.
  • Hyaluronic acid content showed a significant increase in bladder during puerperium.
  • CONCLUSIONS: We observed different composition in vesical and urethral tissues during pregnancy and in puerperium.
  • [MeSH-major] Glycosaminoglycans / metabolism. Pregnancy, Animal / metabolism. Urethra / metabolism. Urinary Bladder / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 1999 Dec 1;75(3):538-46 [10536375.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2002 Nov;13(6):342-5; discussion 345 [12466902.001]
  • [Cites] Rev Assoc Med Bras (1992). 2008 Mar-Apr;54(2):173-7 [18506330.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):250-4 [16314024.001]
  • [Cites] Annu Rev Biochem. 1991;60:443-75 [1883201.001]
  • [Cites] J Intern Med. 1997 Jul;242(1):27-33 [9260563.001]
  • [Cites] J Clin Invest. 2001 Apr;107(8):935-41 [11306594.001]
  • [Cites] Annu Rev Biochem. 1998;67:609-52 [9759499.001]
  • [Cites] Clin Chem. 1991 May;37(5):667-72 [1827758.001]
  • [Cites] Curr Opin Obstet Gynecol. 1999 Oct;11(5):509-15 [10526931.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Jan;77(1):87-94 [9492726.001]
  • [Cites] Anal Biochem. 2003 Aug 1;319(1):65-72 [12842108.001]
  • [Cites] Am J Obstet Gynecol. 2003 Dec;189(6):1654-9 [14710093.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 1;330(1):163-73 [8651691.001]
  • [Cites] Curr Opin Cell Biol. 2000 Oct;12(5):581-6 [10978893.001]
  • [Cites] Lancet. 1996 Jun 15;347(9016):1658-61 [8642960.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Jan;77(1):95-100 [9492727.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1998 May;44(3):417-29 [9620437.001]
  • [Cites] Am J Obstet Gynecol. 2003 Dec;189(6):1597-9; discussion 1599-1600 [14710077.001]
  • [Cites] Obstet Gynecol. 1994 Oct;84(4):583-6 [8090397.001]
  • [Cites] Clin Exp Obstet Gynecol. 2001;28(2):92-6 [11491384.001]
  • [Cites] Am J Obstet Gynecol. 2000 Jun;182(6):1565-74 [10871479.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug;15(4):266-71 [15517672.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):994-8 [9307523.001]
  • [Cites] Anal Biochem. 1976 Feb;70(2):645-7 [131498.001]
  • [Cites] Matrix Biol. 2000 Aug;19(4):325-32 [10963993.001]
  • [Cites] FASEB J. 1994 Aug;8(11):854-61 [7520879.001]
  • (PMID = 19798458.001).
  • [ISSN] 1433-3023
  • [Journal-full-title] International urogynecology journal
  • [ISO-abbreviation] Int Urogynecol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycosaminoglycans
  •  go-up   go-down


6. Melidone R, Parry NM, Gruntman A: Urinary bladder agenesis in an alpaca (Vicugna pacos) cria. J Vet Diagn Invest; 2010 May;22(3):473-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder agenesis in an alpaca (Vicugna pacos) cria.
  • A 10-day-old female alpaca (Vicugna pacos) cria with a history of urinary straining and dribbling was presented for evaluation.
  • An abdominal ultrasound revealed bilateral hydronephrosis and hydroureter, and no urinary bladder was identified.
  • Gross postmortem examination revealed urinary bladder agenesis and bilateral hydronephrosis and hydroureter, with both ureters opening into a sinus in the caudal vagina.
  • [MeSH-major] Animals, Newborn / abnormalities. Urinary Bladder / abnormalities. Urinary Bladder / pathology

  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453232.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8W8T17847W / Urea
  •  go-up   go-down


7. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler M, Hartmann A: MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia; 2010 Aug;12(8):628-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
  • PURPOSE: The role of adjuvant chemotherapy in patients with locally advanced bladder cancer still remains to be defined.
  • EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded tumor samples from 108 patients with locally advanced bladder cancer, who had been enrolled in AUO-AB05/95, a phase 3 trial randomizing a maximum of three courses of adjuvant cisplatin and methotrexate (CM) versus methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC), were included in the study.
  • Tumor cells were retrieved by laser-captured microdissection and analyzed for MDR1 and ERCC1 expression using a quantitative real-time reverse transcription-polymerase chain reaction assay.
  • CONCLUSIONS: High MDR1 and ERCC1 gene expressions are associated with inferior outcome after cisplatin-based adjuvant chemotherapy for locally advanced bladder cancer.
  • Prospective studies are warranted to define a role for MDR1 and ERCC1 analysis in individualizing multimodality treatment in locally advanced bladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / drug therapy. P-Glycoprotein / genetics. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Disease Progression. Endonucleases / genetics. Endonucleases / metabolism. Epirubicin / administration & dosage. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Methotrexate / administration & dosage. Middle Aged. P-Glycoproteins. Prognosis. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1985 Mar;133(3):403-7 [4038749.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] J Urol. 1991 Mar;145(3):459-64; discussion 464-7 [1997689.001]
  • [Cites] Br J Urol. 1991 Jun;67(6):608-15 [2070206.001]
  • [Cites] FASEB J. 1991 Aug;5(11):2523-8 [1868977.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] J Urol. 1995 Jan;153(1):47-52 [7966789.001]
  • [Cites] Urology. 1995 Jan;45(1):47-53 [7817480.001]
  • [Cites] Ann Oncol. 1994 Nov;5(9):835-40 [7848886.001]
  • [Cites] N Engl J Med. 1995 Nov 23;333(21):1380-5 [7477118.001]
  • [Cites] J Urol. 1996 Feb;155(2):495-9; discussion 499-500 [8558644.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1238-42 [8577747.001]
  • [Cites] J Urol. 1996 Jul;156(1):271-5 [8648821.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):309-16 [9440758.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):533-40 [10470696.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4963-74 [15939920.001]
  • [Cites] BJU Int. 2006 Jan;97(1):42-7 [16336326.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):522-8 [17229776.001]
  • [Cites] Blood. 2007 May 15;109(10):4168-70 [17227830.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2741-6 [17602079.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2747-54 [17602080.001]
  • [Cites] J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):721-4 [18231753.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):674-9 [18592007.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1853-9 [18641005.001]
  • [Cites] Acta Med Indones. 2008 Oct;40(4):187-91 [19151448.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2643-50 [19253368.001]
  • [Cites] Minerva Urol Nefrol. 2009 Jun;61(2):91-107 [19451891.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5191-8 [19671876.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5680-4 [19858384.001]
  • [Cites] Pharmacogenomics J. 2010 Feb;10(1):62-9 [19752884.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3352-6 [10589744.001]
  • [Cites] Am J Physiol. 1999 Dec;277(6 Pt 2):F832-40 [10600929.001]
  • [Cites] Blood. 2000 May 1;95(9):2897-904 [10779437.001]
  • [Cites] Biol Pharm Bull. 2003 Feb;26(2):205-9 [12576681.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1466-73 [12689934.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • (PMID = 20689757.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2915407
  •  go-up   go-down


8. Cengiz M, Ozaydin A, Ozkilic AC, Dedekarginoglu G: The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients. Int Urol Nephrol; 2007;39(4):1043-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients.
  • Using the polymerase chain reaction (PCR) the prevalence of genetic polymorphisms of GSTT1, GSTM1 and MnSOD (Manganese Superoxide Dismurase) was investigated in 104 cases and controls to seek any association with the risk of bladder cancer.
  • There was no association between the GSTT1 and SOD polymorphism and bladder cancer incidence.
  • The incidence of the GSTM1 null genotype was increased in bladder cancer patients compared to controls (OR = 1.755, 95% CI = 1.119-2.751).
  • [MeSH-major] Glutathione Transferase / genetics. Polymorphism, Genetic. Superoxide Dismutase / genetics. Urinary Bladder Neoplasms / enzymology. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2000 Jun;37(6):660-4 [10828664.001]
  • [Cites] Int J Epidemiol. 1999 Oct;28(5):829-35 [10597978.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):339-44 [16005379.001]
  • [Cites] Carcinogenesis. 1993 Sep;14(9):1821-4 [8403204.001]
  • [Cites] Biochem J. 1994 May 15;300 ( Pt 1):271-6 [8198545.001]
  • [Cites] Urology. 2002 Nov;60(5):913-8 [12429337.001]
  • [Cites] Am J Ophthalmol. 2000 Dec;130(6):769-73 [11124296.001]
  • [Cites] Adv Clin Chem. 1993;30:281-380 [8237562.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):973-8 [14729580.001]
  • [Cites] Hepatology. 1989 Mar;9(3):486-96 [2646197.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] BMC Med Genet. 2001;2:4 [11299047.001]
  • [Cites] Lancet. 1996 Feb 3;347(8997):295-7 [8569364.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):199-207 [15219943.001]
  • [Cites] J Surg Res. 2005 Mar;124(1):92-7 [15734485.001]
  • [Cites] Int J Biol Markers. 2005 Jan-Mar;20(1):69-72 [15832776.001]
  • [Cites] Neoplasma. 1998;45(5):312-7 [9921921.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 15;146(2):125-9 [14553946.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3915-25 [8752158.001]
  • [Cites] Physiol Res. 1999;48(6):465-71 [10783912.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Feb;125(1):1-4 [11297759.001]
  • [Cites] Free Radic Biol Med. 2004 Mar 15;36(6):718-44 [14990352.001]
  • [Cites] Cancer Lett. 1998 Oct 23;132(1-2):147-52 [10397466.001]
  • [Cites] Urology. 2005 Jan;65(1):70-5 [15667866.001]
  • (PMID = 17340208.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


9. Urushibara M, Kageyama Y, Akashi T, Otsuka Y, Takizawa T, Koike M, Kihara K: HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer. Jpn J Clin Oncol; 2007 Jan;37(1):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer.
  • Expression of HSPs in invasive or high-risk superficial bladder cancer was investigated to identify whether HSPs predict pathological response to neoadjuvant chemoradiotherapy (CRT).
  • METHODS: Immunohistochemistry was used to assess expression levels of HSP27, HSP60, HSP70, HSP90 and p53 in 54 patients with invasive or high-risk superficial bladder cancer, prior to low-dose neoadjuvant CRT, followed by radical or partial cystectomy.
  • Good responders showed morphological therapeutic changes in two-thirds or more of tumor tissues.
  • In contrast, poor responders showed changes in less than two-thirds of tumor tissues.
  • CONCLUSIONS: Positive HSP60 expression prior to CRT may predict good pathological response to low-dose neoadjuvant CRT in invasive or high-risk superficial bladder cancer.
  • [MeSH-major] Chaperonin 60 / metabolism. Urinary Bladder Neoplasms / metabolism


10. Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, Moon SK, Choi YH, Kim WJ: Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res; 2010 Apr 1;16(7):2131-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers.
  • PURPOSE: Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is effective in the prevention of recurrence and progression in many cases of nonmuscle invasive bladder cancer, but many patients fail to respond.
  • The aim of this study was to identify gene sets of markers that could predict the response to BCG immunotherapy in primary pT1 bladder cancer using microarray gene expression profiling.
  • EXPERIMENTAL DESIGN: We used 80 patients with primary pT1 bladder cancer treated with BCG immunotherapy as training (48) and test (32) sets.
  • CONCLUSIONS: Predictive gene signatures have diagnostic value for determining the response to intravesical BCG immunotherapy in primary pT1 bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Gene Expression Profiling. Immunotherapy. Mycobacterium bovis / immunology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Cohort Studies. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [CommentIn] Nat Rev Urol. 2010 Jun;7(6):302 [20545035.001]
  • (PMID = 20233890.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


11. Iijima K, Igawa Y, Imamura T, Moriizumi T, Nikaido T, Konishi I, Nishizawa O: Transplantation of preserved human amniotic membrane for bladder augmentation in rats. Tissue Eng; 2007 Mar;13(3):513-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation of preserved human amniotic membrane for bladder augmentation in rats.
  • Although gastrointestinal segments have been widely used for bladder reconstruction, they are not ideal because of the possible complications.
  • Here, we performed bladder augmentation in rats using human amniotic membrane (hAM).
  • Morphologically, the hAM-augmented bladder revealed regeneration of urothelium, detrusor smooth muscle, and nerve fibers within 3 months post-operatively.
  • In our functional evaluation of bladder strips, we compared hAM-augmented bladders with bladders augmented using small intestinal submucosa (SIS).
  • For example, at 6 months post-operatively, contractions of the following size (as a percentage of the responses in the control-bladder group) were obtained in response to high potassium, carbachol, and electrical field stimulation, respectively: hAM 22% vs SIS 15%, hAM 15% vs SIS 7%, hAM 5.3% vs SIS 1.3% (no significant differences, hAM vs SIS).
  • The present results indicate that, for bladder augmentation, hAM can be used as a scaffold and is comparable in this respect with SIS. hAM can be more easily obtained than SIS and requires little preparation, and its use raises few ethical questions.
  • [MeSH-major] Amnion / transplantation. Tissue Preservation. Urinary Bladder / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17518600.001).
  • [ISSN] 1076-3279
  • [Journal-full-title] Tissue engineering
  • [ISO-abbreviation] Tissue Eng.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Aguirre D, Caiseda D, Correa-Rivas M, Maldonado M, Rodríguez W, Miranda G, Lugo A, Gandia J: A multidisciplinary approach to surgical management of placenta previa percreta with bladder invasion: a case report. P R Health Sci J; 2006 Jun;25(2):163-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multidisciplinary approach to surgical management of placenta previa percreta with bladder invasion: a case report.
  • Placenta previa percreta with bladder invasion occurs rarely.
  • However this disorder has become more common since the increased rate of cesarean deliveries.
  • We present a 26 year old gravida 3, para 2-0-1-2 female with placenta previa, percreta and bladder invasion to stress out the importance of early recognition of this life threatening condition and to point out that the good outcome of this case was mainly due to the multidisciplinary approach chosen during the preoperative and post operative management.
  • A surgical management was chosen since it is the most common and more accepted treatment of placenta previa percreta with bladder invasion.
  • [MeSH-major] Placenta Accreta / surgery. Placenta Previa / surgery. Urinary Bladder Diseases / surgery
  • [MeSH-minor] Adult. Apgar Score. Cesarean Section. Female. Humans. Hysterectomy. Infant, Newborn. Pregnancy. Pregnancy Outcome. Prenatal Care. Ultrasonography, Doppler, Color. Urinary Bladder / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203716.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


13. Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Månsson W: Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol; 2006 Jan;175(1):84-8; discussion 88-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer.
  • PURPOSE: We evaluated intraoperative SN detection in patients with invasive bladder cancer during radical cystectomy in conjunction with extended lymphadenectomy.
  • MATERIALS AND METHODS: A total of 75 patients with invasive bladder cancer underwent radical cystectomy with extended lymphadenectomy.
  • CONCLUSIONS: SN detection is feasible in invasive bladder cancer, although the false- negative rate was 19% in this study.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406877.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sekita N, Egoshi K, Hamano S, Matsuzaki O: [Ileovesical fistula caused by bladder cancer with bladder stone]. Hinyokika Kiyo; 2006 Oct;52(10):793-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileovesical fistula caused by bladder cancer with bladder stone].
  • A case of ileovesical fistula caused by a bladder carcinoma is presented.
  • A 66-year-old male was referred with complaints of urinary pain.
  • On admission, fecaluria and urinary tract infection with bladder stone were detected.
  • Under the diagnosis ofileovesical fistula due to suspected inflammatory disease, sigmoidectomy and segmental small bowel resection with partial cystectomy were performed.
  • Since it has been reported that about 40% of the patients with T4 bladder tumors could be potentially cured with radical resection, we recommend a thorough examination to confirm the diagnosis of primary disease to obtain the best results.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Ileal Diseases / etiology. Intestinal Fistula / etiology. Urinary Bladder Calculi / complications. Urinary Bladder Fistula / etiology. Urinary Bladder Neoplasms / complications


15. Speers AG, Lwaleed BA, Featherstone JM, Sallis BJ, Cooper AJ: Furosemide reverses multidrug resistance status in bladder cancer cells in vitro. J Clin Pathol; 2006 Sep;59(9):912-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
  • MATERIALS AND METHODS: An MDR bladder cancer cell line (MGH-u 1R) and its parental (drug sensitive) clone were exposed to epirubicin and furosemide, with the concentration of one drug fixed and that of the other serially diluted in a 96-well plate format.
  • CONCLUSION: Furosemide is effective in reversing MDR status in bladder cancer cell lines in vitro.
  • We propose a potential for further investigation of furosemide as an adjunct to chemotherapy for superficial bladder cancer.
  • [MeSH-major] Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Furosemide / pharmacology. Sodium Potassium Chloride Symporter Inhibitors / pharmacology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacokinetics. Antibiotics, Antineoplastic / pharmacology. Cell Death / drug effects. Cell Division / drug effects. Dose-Response Relationship, Drug. Epirubicin / pharmacokinetics. Epirubicin / pharmacology. Humans. Microscopy, Confocal. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2001 Feb;87(3):245-50 [11167651.001]
  • [Cites] BJU Int. 2005 May;95(7):1091-8 [15839939.001]
  • [Cites] BJU Int. 2002 Nov;90(7):736-41 [12410758.001]
  • [Cites] J Urol. 1988 Aug;140(2):410-4 [3398164.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1397-401 [2493980.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):521-7 [1636236.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):456-61 [7685326.001]
  • [Cites] Drugs. 1993 May;45(5):788-856 [7686469.001]
  • [Cites] J Urol. 1996 Apr;155(4):1233-8 [8632538.001]
  • [Cites] Br J Urol. 1996 Jun;77(6):819-23 [8705214.001]
  • [Cites] Br J Urol. 1996 Jun;77(6):824-9 [8705215.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):906-9 [8826856.001]
  • [Cites] Cytotechnology. 1996;19(3):181-6 [8862004.001]
  • [Cites] Cytotechnology. 1996;19(3):187-90 [8862005.001]
  • [Cites] Cancer Detect Prev. 1996;20(6):625-33 [8939349.001]
  • [Cites] J Urol. 1997 Apr;157(4):1260-4; discussion 1264-5 [9120915.001]
  • [Cites] Eur Urol. 1999 Apr;35(4):327-35 [10087397.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):847-56 [11396174.001]
  • (PMID = 16556663.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Sodium Potassium Chloride Symporter Inhibitors; 3Z8479ZZ5X / Epirubicin; 7LXU5N7ZO5 / Furosemide
  • [Other-IDs] NLM/ PMC1860466
  •  go-up   go-down


16. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, Sun TT, Wu XR: Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest; 2007 Feb;117(2):314-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.
  • Here we show that low-level expression of a constitutively active Ha-ras in mouse urothelium induces simple urothelial hyperplasia that is resistant to progression to full-fledged bladder tumors even in the absence of Ink4a/Arf.
  • In stark contrast, doubling of the gene dosage of the activated Ha-ras triggered early-onset, rapidly growing, and 100% penetrant tumors throughout the urinary tract.
  • Tumor initiation required superseding a rate-limiting step between simple and nodular hyperplasia, the latter of which is marked by the emergence of mesenchymal components and the coactivation of AKT and STAT pathways as well as PTEN inactivation.
  • These results indicate that overactivation of Ha-ras is both necessary and sufficient to induce bladder tumors along a low-grade, noninvasive papillary pathway, and they shed light on the recent findings that ras activation, via point mutation, overexpression, or intensified signaling from FGF receptor 3, occurs in 70%-90% of these tumors in humans.
  • Finally, our results have clinical implications, as inhibiting ras and/or its downstream effectors, such as AKT and STAT3/5, could provide alternative means to treat low-grade, superficial papillary bladder tumors, the most common tumor in the urinary system.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):829-34 [9563875.001]
  • [Cites] Eur Urol. 1998;33 Suppl 4:2-4 [9615195.001]
  • [Cites] Oncogene. 1998 Jun 18;16(24):3215-8 [9671402.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):3008-19 [9765203.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):441-5 [10024675.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):721-7 [10079249.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):319-25 [10448118.001]
  • [Cites] Am J Med Genet. 1999 Sep 10;86(2):174-9 [10449656.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):18-20 [10471491.001]
  • [Cites] Am J Anat. 1960 Sep;107:95-105 [13782694.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2065-9 [15781613.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):636-7 [16079829.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5218-25 [15897885.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1038-40 [16170316.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1302-12 [16452183.001]
  • [Cites] Nat Clin Pract Urol. 2005 Oct;2(10):502-10 [16474624.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):361-73 [16352616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3633-8 [16537447.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1212-5 [16570285.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):468-72 [10440378.001]
  • [Cites] Am J Med Genet. 2000 Jan 31;90(3):256-9 [10678668.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5010-8 [10866658.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):73-7 [10958945.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):620-5 [11058880.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):514-8 [11102896.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):993-8 [11035045.001]
  • [Cites] Oncogene. 2001 Apr 12;20(16):1973-80 [11360181.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7 [11584300.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1515-21 [11720438.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Exp Cell Res. 2002 Feb 15;273(2):127-37 [11822868.001]
  • [Cites] Cell. 2002 Jan 25;108(2):135-44 [11832204.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):222-31 [11902577.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11107-15 [11799110.001]
  • [Cites] J Pathol. 2002 Apr;196(4):394-400 [11920734.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1651-8 [12075083.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1446-65 [12080084.001]
  • [Cites] J Urol. 2002 Sep;168(3):1133-4 [12187253.001]
  • [Cites] J Pathol. 2003 Jan;199(1):50-7 [12474226.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Toxicol Pathol. 2002 Nov-Dec;30(6):663-71 [12512866.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):737-44 [12910517.001]
  • [Cites] Gene Ther. 2003 Sep;10(19):1636-42 [12923562.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):687-96 [14737103.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):97-105 [14964307.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1911-4 [15026322.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):111-6 [15324694.001]
  • [Cites] Nature. 1982 Jun 10;297(5866):474-8 [6283357.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):149-52 [7133135.001]
  • [Cites] Science. 1983 Jun 10;220(4602):1175-7 [6304875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(22):9047-51 [2247480.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3471-5 [2054786.001]
  • [Cites] Environ Health Perspect. 1991 Jun;93:19-25 [1773791.001]
  • [Cites] Hum Pathol. 1992 Nov;23(11):1199-204 [1427748.001]
  • [Cites] Urol Res. 1993 Jan;21(1):39-43 [8096102.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):166-76 [7906919.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):129-33 [7707384.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4531-5 [7553622.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):241-7 [8947520.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Genes Dev. 1997 Nov 1;11(21):2822-34 [9353252.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1090-4 [9515785.001]
  • (PMID = 17256055.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK056903; United States / NIDDK NIH HHS / DK / DK69688; United States / NIDDK NIH HHS / DK / R01 DK069688; United States / NIDDK NIH HHS / DK / DK52206; United States / NIDDK NIH HHS / DK / P01 DK052206; United States / NIDDK NIH HHS / DK / DK56903
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Primers; 0 / STAT Transcription Factors; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC1770948
  •  go-up   go-down


17. Amsellem-Ouazana D, Bièche I, Molinié V, Elie C, Vieillefond A, Tozlu S, Botto H, Debré B, Lidereau R: Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? Eur Urol; 2006 Jun;49(6):1035-42; discussion 1042-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?
  • OBJECTIVE: To test different approaches of evaluation of the ErbB2 status in a large series of human transitional cell carcinoma (TCC) of the bladder with the prospect of finding targeted therapies.
  • Additionally, 18 bladder samples were studied for ERBB2 gene amplification by real-time quantitative PCR.
  • RESULTS: Twenty-five tumors (34.2%) overexpressed ERBB2 mRNA compared to normal bladder samples; this alteration appeared in low-grade and low-stage tumors (pTaG1).
  • Twenty-four (32.9%) tumors showed moderate (++) or strong (+++) immunostaining.
  • ErbB2 status was not associated with tumor stage.
  • Of the 18 bladder samples tested for ERBB2 gene amplification, only one showed ERBB2 DNA amplification.
  • CONCLUSIONS: ErbB2 overexpression occurs in about one third of bladder TCCs.
  • Accurate quantification of ErbB2 status is mandatory for the use of anti-ErbB2-targeted therapies in bladder TCC.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Gene Expression Regulation, Neoplastic. RNA, Messenger / analysis. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466848.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


18. Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y: Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology; 2009 Apr;251(1):112-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade.
  • PURPOSE: To prospectively evaluate the ability of diffusion-weighted (DW) magnetic resonance (MR) imaging to be used to determine the T stage of bladder cancer and to measure the correlation between the apparent diffusion coefficient (ADC) and histologic grade.
  • Forty patients with a total of 52 bladder tumors underwent MR imaging that included DW imaging.
  • Histologic grade was determined for all tumors.
  • For DW images, new staging criterion developed on the basis of the hypothesis that tumors, submucosal tissue, and muscles show high, low, and intermediate signal intensity, respectively, was used.
  • RESULTS: The overall accuracy of T stage diagnosis was 67% for T2-weighted images alone, 88% for T2-weighted plus DW images, 79% for T2-weighted plus contrast-enhanced images, and 92% for all three image types together.
  • The mean ADC of G3 tumors was significantly lower than that of G1 and G2 tumors (P < .01).
  • CONCLUSION: DW images provided useful information for evaluating the T stage of bladder cancer, particularly in differentiating T1 or lower tumors from T2 or higher tumors.
  • The ADC may in part predict the histologic grade of bladder cancer.
  • [MeSH-major] Algorithms. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Neoplasm Staging / methods. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332849.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Hernández-Zavala A, Valenzuela OL, Matousek T, Drobná Z, Dĕdina J, García-Vargas GG, Thomas DJ, Del Razo LM, Stýblo M: Speciation of arsenic in exfoliated urinary bladder epithelial cells from individuals exposed to arsenic in drinking water. Environ Health Perspect; 2008 Dec;116(12):1656-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Speciation of arsenic in exfoliated urinary bladder epithelial cells from individuals exposed to arsenic in drinking water.
  • Relative proportions of urinary metabolites of iAs have been identified as potential biomarkers of susceptibility to iAs toxicity.
  • OBJECTIVE: In this study we examined the feasibility of analyzing As species in cells that originate in the urinary bladder, a target organ for As-induced cancer in humans.
  • METHODS: Exfoliated bladder epithelial cells (BECs) were collected from urine of 21 residents of Zimapan, Mexico, who were exposed to iAs in drinking water.
  • CONCLUSION: These results suggest that urinary levels of iAs metabolites do not necessarily reflect levels of these metabolites in the bladder epithelium.
  • Thus, analysis of As species in BECs may provide a more effective tool for risk assessment of bladder cancer and other urothelial diseases associated with exposures to iAs.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Res Toxicol. 2001 Apr;14(4):371-8 [11304125.001]
  • [Cites] Chem Res Toxicol. 2001 Jun;14(6):651-6 [11409934.001]
  • [Cites] Mol Pharmacol. 2001 Aug;60(2):302-9 [11455017.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Aug 1;174(3):282-93 [11485389.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):127-44 [11601889.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10795-803 [11790780.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:767-71 [12426129.001]
  • [Cites] FASEB J. 2003 Jan;17(1):67-9 [12475910.001]
  • [Cites] J Occup Environ Med. 2003 Mar;45(3):241-8 [12661181.001]
  • [Cites] Eur J Cell Biol. 2003 Jul;82(7):343-50 [12924629.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1974 Jul 25;268(891):23-38 [4155088.001]
  • [Cites] Urol Res. 1993 Jan;21(1):23-6 [8456534.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):583-90 [7827589.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):31-6 [8993795.001]
  • [Cites] Arch Toxicol. 1997;71(4):211-7 [9101036.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):185-95 [9219557.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):207-12 [10328596.001]
  • [Cites] Environ Health Perspect. 2005 Mar;113(3):250-4 [15743710.001]
  • [Cites] Reprod Biomed Online. 2005 Jun;10(6):755-66 [15970006.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Sep 1;207(2):147-59 [16102566.001]
  • [Cites] Environ Health Perspect. 2006 Apr;114(4):527-31 [16581540.001]
  • [Cites] Chem Res Toxicol. 2006 Jul;19(7):894-8 [16841956.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Jan;232(1):3-13 [17202581.001]
  • [Cites] Environ Health Perspect. 2007 May;115(5):734-42 [17520061.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):264-70 [17267001.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):374-80 [17276472.001]
  • [Cites] Chem Res Toxicol. 2007 Aug;20(8):1120-5 [17630711.001]
  • [Cites] Mutat Res. 1999 Dec 13;446(2):175-80 [10635339.001]
  • [Cites] Chem Res Toxicol. 2000 Aug;13(8):693-7 [10956055.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33404-8 [10938093.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1259-62 [11097236.001]
  • [Cites] Environ Health Perspect. 2000 Nov;108(11):1015-8 [11102289.001]
  • [Cites] Arch Toxicol. 2000 Dec;74(10):618-26 [11201669.001]
  • [Cites] Chem Res Toxicol. 2001 Apr;14(4):355-61 [11304123.001]
  • (PMID = 19079716.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / R03 TW007057; United States / FIC NIH HHS / TW / 1R03 TW 007057
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Water Pollutants, Chemical; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC2599759
  • [Keywords] NOTNLM ; arsenic species / drinking water / exfoliated human urinary bladder epithelial cells
  •  go-up   go-down


20. Hayashi T, Abe T, Nakayama J, Mori N, Sekii K, Yoshioka T, Itatani H, Kishikawa H: [A case of inflammatory myofibroblastic tumor of the bladder]. Hinyokika Kiyo; 2006 Dec;52(12):955-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inflammatory myofibroblastic tumor of the bladder].
  • Here we report a rare case of inflammatory myofibroblastic tumor of the bladder.
  • We diagnosed this case preoperatively as urachal tumor from urine cytology, cystoscopy, and magnetic resonance imaging.
  • Histopathological examination revealed that the tumor was an inflammatory myofibroblastic tumor.
  • To our knowledge, this is the 51st reported case of inflammatory myofibroblastic tumor of the bladder in Japan.
  • [MeSH-major] Neoplasms, Muscle Tissue / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252981.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Chen Z, Tan WL, Huang X, Liang ZK, Xu CX, Gao JM: [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):936-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
  • OBJECTIVE: To investigate a novel immunotherapy through immobilization of streptavidin-tagged hTNF-alpha on the biotinylated mucosal surface of the bladder wall for bladder cancer treatment in mice.
  • Twenty-four hours after establishment of a mouse model of orthotopic superficial bladder cancer, SA-hTNF-alpha fusion protein was immobilized on the biotinylated mucosal surface of the bladder wall, which was repeated every 4 days for a total of 6 sessions.
  • Immunohistochemistry was performed to detect the retention time of SA-hTNF-alpha fusion protein in the biotinylated mouse bladder mucosa and the distribution of CD4(+) and CD8(+) lymphocytes in the mucosa and tumor tissues, with the tumor growth and mouse survival also observed.
  • The cytotoxiciy of the tumor-specific lymphocytes was evaluated.
  • RESULTS: SA-hTNF-alpha could be efficiently and stably immobilized on the bladder mucosal surface for as long as 7 days.
  • On day 60 after MB49 implantation, 18 out of 22 SA- hTNF-alpha-treated mice survived, with 9 appearing tumor-free, but all the mice in PBS control group died.
  • Five out of 9 tumor-free mice in SA-hTNF-alpha group showed resistance to a re-challenge with intravesical MB49.
  • The cytotoxicity of the tumor-specific lymphocytes was significantly stronger in SA-hTNF-alpha group than in the other groups (P<0.05).
  • CONCLUSION: SA-hTNF-alpha immobilized on the biotinylated mucosal surface of the bladder wall can significantly inhibit the tumor growth and promote the survival of the mice bearing orthotopic superficial bladder cancer.
  • [MeSH-major] Immobilized Proteins / therapeutic use. Immunotherapy / methods. Streptavidin / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501361.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immobilized Proteins; 0 / Recombinant Fusion Proteins; 0 / Tumor Necrosis Factor-alpha; 9013-20-1 / Streptavidin
  •  go-up   go-down


22. Hirao S, Hirao T, Marsit CJ, Hirao Y, Schned A, Devi-Ashok T, Nelson HH, Andrew A, Karagas MR, Kelsey KT: Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer; 2005 Nov 1;104(9):1918-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer.
  • BACKGROUND: Somatic loss of the 9q allele as well as alteration of the tumor suppressor p53 occurs commonly in bladder cancers.
  • METHODS: The 9q LOH was examined at five microsatellites and p53 alterations (mutation and persistent immunohistochemical staining) in a population-based case series of 271 newly diagnosed bladder cancer patients.
  • CONCLUSIONS: These data, using a population-based sample, suggest a relation between 9q LOH and invasive stage bladder cancer, and thereby suggests that a tumor suppressor gene at this loci, in addition to p53, may be important in the development of this more aggressive form of the disease.
  • [MeSH-major] Chromosomes, Human, Pair 9. Genes, p53. Loss of Heterozygosity. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16149093.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES000002; United States / NIEHS NIH HHS / ES / P42 ES005947; United States / NIEHS NIH HHS / ES / P42 ES007373
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


23. Kuo HC, Liu HT, Chancellor MB: Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn; 2010 Mar;29(3):482-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
  • PURPOSE: To compare the differences in urinary nerve growth factor (NGF) and detrusor wall thickness (DWT) between patients with overactive bladder (OAB) and controls to evaluate their suitability as biomarkers in OAB.
  • Urine NGF and DWT measurements were performed at full bladder and urge to void after natural-filling or catheter-filling during videourodynamic study.
  • Urinary NGF level was measured by the ELISA method and DWT was measured by trans-abdominal ultrasound.
  • RESULTS: DWT was not significantly different among subgroups at 250 ml bladder volume.
  • Although patients with OAB wet had a significantly greater DWT at the maximal bladder volume, this difference was not significant from controls after correction of the volume factor.
  • By contrast, urinary NGF levels were significantly increased in patients with OAB wet and those with urodynamic detrusor overactivity.
  • CONCLUSIONS: Urinary NGF level in natural-filling urine sample is a better biomarker for assessment of OAB wet compared to DWT.
  • Patients with OAB dry or hypersensitive bladder did not have an elevated urinary NGF level.
  • [MeSH-major] Nerve Growth Factor / urine. Urinary Bladder / pathology. Urinary Bladder, Overactive / pathology. Urinary Bladder, Overactive / urine. Urinary Incontinence / pathology. Urinary Incontinence / urine

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19367641.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 9061-61-4 / Nerve Growth Factor
  •  go-up   go-down


24. Chen SH, Wang YW, Hsu JL, Chang HY, Wang CY, Shen PT, Chiang CW, Chuang JJ, Tsai HW, Gu PW, Chang FC, Liu HS, Chow NH: Nucleophosmin in the pathogenesis of arsenic-related bladder carcinogenesis revealed by quantitative proteomics. Toxicol Appl Pharmacol; 2010 Jan 15;242(2):126-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin in the pathogenesis of arsenic-related bladder carcinogenesis revealed by quantitative proteomics.
  • This study reports the potential significance of nucleophosmin (NPM) in the As-related bladder carcinogenesis.
  • NPM was universally expressed in all of uroepithelial cell lines examined, implying that NPM may play a role in human bladder carcinogenesis.
  • The results suggest that NPM may play a role in the As-related bladder carcinogenesis, and soybean-based foods may have potential in the suppression of As/NPM-related tumorigenesis.
  • [MeSH-major] Arsenic / toxicity. Carcinogens / toxicity. Nuclear Proteins / physiology. Proteomics. Urinary Bladder Neoplasms / chemically induced
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Line, Tumor. Chromatography, Liquid. DNA Primers. Humans. Polymerase Chain Reaction. RNA Interference. Tandem Mass Spectrometry

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818359.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA Primers; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; N712M78A8G / Arsenic
  •  go-up   go-down


25. Ku JH, Kim Y, Moon KC, Kim YS, Kim MS, Kim HH, Paick JS: In vivo hepatocyte growth factor gene transfer to bladder smooth muscle after bladder outlet obstruction in the rat: a morphometric analysis. J Urol; 2006 Sep;176(3):1230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo hepatocyte growth factor gene transfer to bladder smooth muscle after bladder outlet obstruction in the rat: a morphometric analysis.
  • PURPOSE: We determined whether hepatocyte growth factor gene transfer after partial bladder outlet obstruction would prove effective for decreasing transforming growth factor-beta expression and consequently decreasing collagen deposition in partially obstructed rat bladders.
  • MATERIALS AND METHODS: Ten-week-old male Sprague-Dawley rats were divided into 3 groups of 10 each, including group 1--sham operation, group 2--bladder outlet obstruction for 4 weeks and group 3--hepatocyte growth factor gene transfer after bladder outlet obstruction.
  • Two weeks after the onset of bladder outlet obstruction in group 3 hepatocyte growth factor-liposome complex (50 microg human hepatocyte growth factor cDNA) was injected into the smooth muscle of the rats.
  • RESULTS: We noted no difference between groups 2 and 3 with regard to the ratio of bladder weight to body weight.
  • CONCLUSIONS: These findings may imply a possible novel therapeutic strategy against bladder dysfunction arising in patients with bladder outlet obstruction.
  • [MeSH-major] Hepatocyte Growth Factor / genetics. Urinary Bladder Neck Obstruction / therapy
  • [MeSH-minor] Animals. Collagen / metabolism. Gene Transfer Techniques. Male. Muscle, Smooth / metabolism. Muscle, Smooth / pathology. Rats. Rats, Sprague-Dawley. Transforming Growth Factor beta / biosynthesis. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890731.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 67256-21-7 / Hepatocyte Growth Factor; 9007-34-5 / Collagen
  •  go-up   go-down


26. Prizment AE, Anderson KE, Harlow BL, Folsom AR: Reproductive risk factors for incident bladder cancer: Iowa Women's Health Study. Int J Cancer; 2007 Mar 1;120(5):1093-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive risk factors for incident bladder cancer: Iowa Women's Health Study.
  • We studied the association between reproductive factors and bladder cancer incidence in a prospective cohort study of 37,459 Iowa women aged 55-69 years and initially free from cancer in 1986.
  • After adjusting for age and smoking, there was an inverse association between age at menopause and incident bladder cancer (n = 192).
  • Compared with menopause at age > or =48, the hazard ratio (HR) of bladder cancer was 1.32 (95% CI; 0.90-1.94) for menopause at 43-47, and 1.60 (95% CI; 1.06-2.39) for < or =42 (p-trend = 0.02).
  • In addition, women with a history of bilateral oophorectomy had an increased risk of bladder cancer compared with those who did not undergo bilateral oophorectomy: HR = 1.58 (95% CI; 1.12, 2.22).
  • Finally, there was an indication of a positive association between bladder cancer and shorter lifetime years of ovulation (p-trend = 0.09).
  • There were no associations between incident bladder cancer and age at first birth, number of births, age at menarche, use of hormone replacement therapy or any other reproductive characteristics.
  • This study provides evidence that increased risk of bladder cancer is associated with earlier age at menopause in postmenopausal women.
  • [MeSH-major] Reproductive History. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131327.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA39742
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


27. Liu HT, Kuo HC: Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol; 2008 Jun;179(6):2270-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder.
  • PURPOSE: The clinical diagnosis of overactive bladder has great variation and is based on subjective symptoms.
  • This study was designed to measure urinary nerve growth factor levels in patients with different types of overactive bladder and to evaluate whether urinary nerve growth factor could be a biomarker for the diagnosis of overactive bladder.
  • MATERIALS AND METHODS: Urinary nerve growth factor levels were measured in patients with increased bladder sensation, overactive bladder dry and overactive bladder wet, and in a group of control subjects without lower urinary tract symptoms.
  • Measurement of urinary nerve growth factor levels was performed by the enzyme-linked immunosorbent assay.
  • The total urinary nerve growth factor levels were then normalized to the concentration of urinary creatinine (nerve growth factor/creatinine level).
  • RESULTS: Urinary nerve growth factor/creatinine levels were low in normal controls (0.041 +/- 0.026) and patients with increased bladder sensation (0.033 +/- 0.02).
  • Patients with overactive bladder dry (0.39 +/- 0.08) or overactive bladder wet (1.7 +/- 0.26) had significantly higher urinary nerve growth factor levels compared to the controls and patients with increased bladder sensation.
  • Patients with overactive bladder wet had significantly higher urinary nerve growth factor levels than those with overactive bladder dry (p = 0.000).
  • The sensitivity of a urinary nerve growth factor/creatinine level of more than 0.05 in the diagnosis of overactive bladder dry or overactive bladder wet was 67.9% and the specificity was 93.8%.
  • CONCLUSIONS: Patients with overactive bladder dry or overactive bladder wet had significantly higher urinary nerve growth factor levels compared to the control group and patients with increased bladder sensation.
  • Urinary nerve growth factor levels could be a potential biomarker for the diagnosis of overactive bladder.
  • [MeSH-major] Nerve Growth Factor / urine. Urinary Bladder, Overactive / diagnosis. Urinary Bladder, Overactive / urine


28. Rijkhorst EJ, Lakeman A, Nijkamp J, de Bois J, van Herk M, Lebesque JV, Sonke JJ: Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
  • PURPOSE: To quantify and evaluate the accumulated prostate, rectum, and bladder dose for several strategies including rotational organ motion correction for intensity-modulated radiotherapy (IMRT) of prostate cancer using realistic organ motion data.
  • Prostate, rectum, and bladder doses were accumulated for each patient, plan, and strategy.
  • Minimum CTV dose (D(min)), rectum equivalent uniform dose (EUD, n = 0.13), and bladder surface receiving >or=78 Gy (S78), were calculated.
  • Margin reduction lowered the rectum EUD(n = 0.13) by approximately 2.6 Gy, and the bladder S78 by approximately 1.9%.
  • Margin reduction combined with online corrections resulted in a similar or lower dose to the rectum and bladder.
  • [MeSH-major] Movement. Prostate / radiation effects. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods. Rectum / radiation effects. Urinary Bladder / radiation effects
  • [MeSH-minor] Calibration. Humans. Male. Radiation Injuries / prevention & control. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Rotation. Seminal Vesicles / radiation effects. Seminal Vesicles / radiography. Technology, Radiologic / methods. Tomography, X-Ray Computed. Treatment Outcome. Tumor Burden


29. Boemers TM, Schimke CM, Ludwikowski B, Ardelean MA: Rotundum psoas hitch: a new method for colpohysteropexy in girls with bladder exstrophy. J Pediatr Urol; 2005 Oct;1(5):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rotundum psoas hitch: a new method for colpohysteropexy in girls with bladder exstrophy.
  • Female patients with bladder exstrophy frequently suffer from uterine prolapse, which is due to a defective pelvic floor anatomy.
  • We describe here a new technique for uteropexy in girls and women with bladder exstrophy.
  • In all but one case, RPH was combined with continent urinary reconstruction.
  • RPH is an effective means of preventing or correcting procidentia in patients with bladder exstrophy; we emphasize that it should be combined with other abdominal operations, such as continent reconstruction, in girls or women with this condition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947565.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Ratanarapee S, Uiprasertkul M, Pradniwat K, Soontrapa S: Villous adenoma of the urinary bladder: a case report. J Med Assoc Thai; 2010 Nov;93(11):1336-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma of the urinary bladder: a case report.
  • Villous adenomas of the urinary tract are rare, in contrast to urothelial neoplasms.
  • The authors reported a case of urinary bladder villous adenoma in a 41-year-old Thai patient who complained of hematuria for one day without any other symptom.
  • Cystoscopic examination revealed a papillary growth at the bladder neck associated with marked degree of bullous edema and bilateral mild hydroureters.
  • The clinical diagnosis was urothelial carcinoma.
  • The tumor showed identical immunohistochemical profile to colonic villous adenoma.
  • The patient has been well for more than a year after tumor removal.
  • [MeSH-major] Adenoma, Villous / pathology. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114216.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


31. Sawhney R, Bourgeois D, Chaudhary UB: Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. Ann Oncol; 2006 Sep;17(9):1360-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead.
  • Randomized clinical trials of neo-adjuvant cisplatin-based combination chemotherapy for locally advanced muscle invasive bladder cancer has shown a survival benefit over cystectomy alone.
  • Future clinical trials incorporating targeted therapies with novel clinical end points may accelerate development of therapeutic strategies for locally advanced muscle invasive bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497827.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 65
  •  go-up   go-down


32. Botto H: [What is the best bladder replacement]. Ann Urol (Paris); 2005 Nov;39 Suppl 5:S120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What is the best bladder replacement].
  • [Transliterated title] Quel est le meilleur remplacement de vessie?
  • Among the surgical options for bladder replacement proposed after cystectomy, the ileocaecal pouch system has been abandoned for twenty years because of its poor gastrointestinal tolerance.
  • However, replacement with the ileum is today the reference cystoplasty with three main techniques: Hautmann bladder, Studer pouch and Foch Z-shaped pouch.
  • Efficacy in terms of urinary continence is optimized by the preparation of a detubularized neobladder with a "physiological" functional capacity, the preservation of the sphincter as well as perineal-abdominal re-education which is started immediately after surgery.
  • Direct ureteral reimplantation in the detubularized bladder is today an effective and sufficient technique to prevent vesico-renal reflux.
  • Tumor recurrences do not seem be dependent on the type of ureteral reimplantation, nor on the type of initial bladder tumor.
  • Extemporaneous examination of the cross-section of normal urethral section (no tumor, dysplasia, or carcinoma in situ) makes it possible to exclude the risk of urethral recurrence.
  • [MeSH-major] Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425729.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


33. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, Shortliffe L, Weissman IL: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A; 2009 Aug 18;106(33):14016-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells.
  • Major clinical issues in bladder cancer include the identification of prediction markers and novel therapeutic targets for invasive bladder cancer.
  • In the current study, we describe the isolation and characterization of a tumor-initiating cell (T-IC) subpopulation in primary human bladder cancer, based on the expression of markers similar to that of normal bladder basal cells (Lineage-CD44(+)CK5(+)CK20(-)).
  • The bladder T-IC subpopulation was defined functionally by its enriched ability to induce xenograft tumors in vivo that recapitulated the heterogeneity of the original tumor.
  • Further, molecular analysis of more than 300 bladder cancer specimens revealed heterogeneity among activated oncogenic pathways in T-IC (e.g., 80% Gli1, 45% Stat3, 10% Bmi-1, and 5% beta-catenin).
  • Despite this molecular heterogeneity, we identified a unique bladder T-IC gene signature by gene chip analysis.
  • This T-IC gene signature, which effectively distinguishes muscle-invasive bladder cancer with worse clinical prognosis from non-muscle-invasive (superficial) cancer, has significant clinical value.
  • Finally, we found that CD47, a protein that provides an inhibitory signal for macrophage phagocytosis, is highly expressed in bladder T-ICs compared with the rest of the tumor.
  • Blockade of CD47 by a mAb resulted in macrophage engulfment of bladder cancer cells in vitro.
  • In summary, we have identified a T-IC subpopulation with potential prognostic and therapeutic value for invasive bladder cancer.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 May 6;121(3):465-77 [15882627.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):778-89 [16432078.001]
  • [Cites] Nat Med. 2006 Mar;12(3):296-300 [16520777.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Nat Rev Immunol. 2006 Jun;6(6):457-64 [16691243.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):239-45 [17291742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D871-7 [17989087.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):345-9 [18202660.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):672-9 [18445819.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] J Natl Cancer Inst. 1970 Nov;45(5):1039-45 [18605432.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):780-3 [19194462.001]
  • [Cites] Urol Oncol. 2009 May-Jun;27(3):268-76 [18440840.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Cell. 2003 May 30;113(5):643-55 [12787505.001]
  • [Cites] Curr Opin Oncol. 2004 May;16(3):257-62 [15069323.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):111-6 [15324694.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):720-8 [15343391.001]
  • [Cites] Am J Clin Pathol. 1982 Nov;78(5):690-4 [7137110.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2259-65 [6372991.001]
  • [Cites] Anticancer Res. 1992 Mar-Apr;12(2):577-83 [1349799.001]
  • [Cites] Genes Dev. 1998 Jul 1;12(13):2048-60 [9649508.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):335-42 [9827902.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • (PMID = 19666525.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K99 CA129640; United States / NCI NIH HHS / CA / K99 CA129640-02; United States / NCI NIH HHS / CA / R00 CA129640-03S1; United States / NCI NIH HHS / CA / R00 CA129640-04; United States / NCI NIH HHS / CA / R00 CA129640-05; United States / NCI NIH HHS / CA / K99/R00 CA129640-02; United States / NCI NIH HHS / CA / R00 CA129640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Keratin-20; 0 / Keratin-5
  • [Other-IDs] NLM/ PMC2720852
  •  go-up   go-down


34. Myers-Irvin JM, Landsittel D, Getzenberg RH: Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol; 2005 Jul;174(1):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the novel marker BLCA-1 for the detection of bladder cancer.
  • PURPOSE: Bladder cancer specific nuclear structural alterations have been identified.
  • We examined the expression pattern of one of these proteins, BLCA-1, in tissue and urine samples from individuals with bladder cancer as well as in samples from normal controls.
  • RESULTS: BLCA-1 was detectable in tissue from patients with bladder cancer but not in normal adjacent areas of the bladder or in normal donor bladder tissue.
  • This protein was also detectable in the urine of patients with bladder cancer by immunoblot and immunoassay.
  • Using a cutoff of 0.025 optical density units (absorbance value) BLCA-1 was detected in 20 of 25 urine samples from patients with bladder cancer but in only 6 of 46 normal, high risk, prostate or renal cancer samples tested, resulting in a test with 80% sensitivity and 87% specificity.
  • Expression of this protein did not appear to correlate with tumor grade.
  • CONCLUSIONS: This research indicates that BLCA-1 is a urine based marker of bladder cancer which may be useful for the detection of this disease.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947579.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA82522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / BLCAP protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


35. Palmer MH, Hardin SR, Behrend C, Collins SK, Madigan CK, Carlson JR: Urinary incontinence and overactive bladder in patients with heart failure. J Urol; 2009 Jul;182(1):196-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary incontinence and overactive bladder in patients with heart failure.
  • PURPOSE: We explored the nature of the relationship between heart failure and urinary symptoms, specifically urinary incontinence and overactive bladder.
  • MATERIALS AND METHODS: An 81-item written survey about urinary incontinence, urgency, frequency, nocturia and other symptoms was administered to hospitalized and clinic patients with heart failure.
  • RESULTS: Of 408 respondents 296 (average age 62.2 years) had information about heart failure stage and urinary symptoms.
  • Of these respondents 45% and 57% reported urinary incontinence and overactive bladder, respectively.
  • Adjusted odds ratio for having overactive bladder over no symptoms for respondents with New York Heart Association Class III or Class IV heart failure was 2.9 (95% CI 1.344-6.250) and for higher fatigue-depression composite was 2.155 (95% CI 1.206-3.860).
  • Adjusted odds ratio for having overactive bladder over frequency/nocturia for respondents with higher body mass index was 1.458 (95% CI 1.087-1.953) and for higher fatigue-depression composite was 1.629 (95% CI 1.038-2.550).
  • CONCLUSIONS: Urinary incontinence and overactive bladder are prevalent in patients with heart failure.
  • Evidence of late stage heart failure, higher fatigue-depression composite and higher body mass index were associated with overactive bladder.
  • Sex, age and diuretic use were not associated with urinary incontinence and overactive bladder.
  • [MeSH-major] Heart Failure / epidemiology. Urinary Bladder, Overactive / epidemiology. Urinary Incontinence / epidemiology


36. Vizzard MA: Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury. Prog Brain Res; 2006;152:97-115
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury.
  • Transection of the spinal cord that interrupts the spinobulbospinal micturition reflex pathway, abolishes voluntary voiding and initially produces an areflexic bladder with complete urinary retention.
  • However, depending upon the species, reflex bladder activity slowly recovers over the course of weeks or months.
  • In chronic spinal animals, reflex mechanisms in the lumbosacral spinal cord are capable of duplicating many of the functions performed by reflex pathways in animals with an intact spinal cord and can induce bladder hyperreflexia.
  • However, the bladder does not empty efficiently due to a loss of bladder-sphincter coordination (bladder-sphincter dyssynergia).
  • In contrast to normal animals in which the sphincter relaxes during voiding, animals with a spinal cord injury exhibit sphincter contractions during voiding, an increase in urethral outlet resistance, urinary retention, bladder hyperreflexia, bladder overdistension, and an increase in bladder afferent cell size.
  • Changes in electrophysiological or neurochemical properties of bladder afferent cells in the dorsal root ganglia and of spinal pathways could contribute to the emergence of the spinal micturition reflex, bladder hyperreflexia and changes in the pharmacologic responses of reflex pathways in the lumbosacral spinal cord after spinal cord injury.
  • Urinary bladder hyperreflexia after spinal cord injury may reflect a change in the balance of neuroactive compounds in bladder reflex pathways.
  • (1) changes in the neurochemical phenotype of bladder afferent neurons and of spinal neurons mediating micturition reflexes after spinal cord injury, with an emphasis on three neuroactive compounds, neuronal nitric oxide synthase (nNOS), galanin, and pituitary adenylate cyclase activating polypeptide (PACAP);.
  • (2) possible functional consequences on bladder reflexes of changes in spinal cord neurochemistry after spinal cord injury, and (3) the potential role of neurotrophic factors expressed in the urinary bladder or spinal cord after spinal cord injury in mediating these neurochemical changes.
  • [MeSH-major] Nerve Growth Factors / metabolism. Neuronal Plasticity / physiology. Neurotransmitter Agents / metabolism. Reflex. Spinal Cord Injuries / physiopathology. Urinary Bladder / innervation

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198696.001).
  • [ISSN] 0079-6123
  • [Journal-full-title] Progress in brain research
  • [ISO-abbreviation] Prog. Brain Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK051369; United States / NIDDK NIH HHS / DK / DK060481; United States / NIDDK NIH HHS / DK / DK065989; United States / NINDS NIH HHS / NS / NS040796; United States / NIDDK NIH HHS / DK / R01 DK051369-06A1; United States / NIDDK NIH HHS / DK / R01 DK051369-07; United States / NIDDK NIH HHS / DK / R01 DK051369-08; United States / NIDDK NIH HHS / DK / R01 DK060481-02; United States / NIDDK NIH HHS / DK / R01 DK060481-03; United States / NIDDK NIH HHS / DK / R01 DK060481-04; United States / NIDDK NIH HHS / DK / R01 DK065989-01; United States / NIDDK NIH HHS / DK / R01 DK065989-02; United States / NINDS NIH HHS / NS / R01 NS040796-01; United States / NINDS NIH HHS / NS / R01 NS040796-02; United States / NINDS NIH HHS / NS / R01 NS040796-03; United States / NINDS NIH HHS / NS / R01 NS040796-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Neurotransmitter Agents; 0 / Pituitary Adenylate Cyclase-Activating Polypeptide; 31C4KY9ESH / Nitric Oxide; 88813-36-9 / Galanin
  • [Number-of-references] 95
  •  go-up   go-down


37. Igawa Y, Aizawa N, Homma Y: Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol; 2010 Dec;51(12):811-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder.
  • In the present review article, we present an overview of beta-adrenoceptor (β-AR) subtype expression at the mRNA and receptor protein levels in the human detrusor, the in vitro and in vivo bladder function of the β3-AR, the in vivo effect of β3-AR agonists on detrusor overactivity in animal models, and the available results of clinical trials of β3-AR agonists for treating overactive bladder (OAB).
  • There is a predominant expression of β3-AR mRNA in human bladder, constituting 97% of total β-AR mRNA.
  • Moreover, the presence of β1-, β2-, and β3-AR mRNAs in the urothelium and suburothelial layer of human bladder has been identified.
  • Intravenous application of CL316,243, a selective β3-AR agonist, in rats selectively inhibits mechano-sensitive Aδ-fiber activity of the primary bladder afferents.
  • The β3-AR agonists act to facilitate bladder storage function probably through at least two mechanisms: first, direct inhibition of the detrusor, and second, inhibition of bladder afferent neurotransduction.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1999 Mar;288(3):1367-73 [10027879.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1310-4 [17026593.001]
  • [Cites] Br J Pharmacol. 1999 Aug;127(7):1744-50 [10455334.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):47-9; discussion 50 [10767451.001]
  • [Cites] J Urol. 2001 Jan;165(1):240-4 [11125417.001]
  • [Cites] J Urol. 2001 Sep;166(3):1142-7 [11490313.001]
  • [Cites] J Neurosci. 2002 Sep 15;22(18):8063-70 [12223560.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):649-53 [12853849.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):654-8 [12853850.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Apr;313(1):260-7 [15576470.001]
  • [Cites] BJU Int. 2007 Mar;99(3):669-73 [17407521.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):473-81 [18311486.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jul;326(1):178-85 [18413856.001]
  • [Cites] Pharmacol Res. 2009 Apr;59(4):221-34 [19429463.001]
  • [Cites] Neurourol Urodyn. 2010 Jun;29(5):771-6 [19816919.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2010 Aug;382(2):103-8 [20517594.001]
  • [Cites] Nature. 1984 May 10-16;309(5964):163-5 [6325935.001]
  • [Cites] J Urol. 1999 Feb;161(2):680-5 [9915482.001]
  • [Cites] J Smooth Muscle Res. 2000 Feb;36(1):21-32 [10830475.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2007 Feb;374(5-6):385-98 [17211601.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):642-7 [17293563.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Aug;322(2):631-7 [17473176.001]
  • [Cites] Neurourol Urodyn. 2007;26(6):752-6 [17600372.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Oct;323(1):202-9 [17626794.001]
  • [Cites] Neurourol Urodyn. 2010 Sep;29(7):1320-5 [20151470.001]
  • [Cites] Eur Urol. 2010 Aug;58(2):249-50 [20471157.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jun;269(3):1000-6 [7912272.001]
  • [Cites] Trends Pharmacol Sci. 1996 Oct;17(10):373-81 [8979772.001]
  • [Cites] Br J Pharmacol. 1997 Dec;122(8):1720-4 [9422819.001]
  • [Cites] Br J Pharmacol. 1998 Jun;124(3):593-9 [9647486.001]
  • [Cites] Br J Pharmacol. 1979 Feb;65(2):215-22 [216452.001]
  • [Cites] Science. 1989 Sep 8;245(4922):1118-21 [2570461.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1997;37:421-50 [9131260.001]
  • [Cites] Acta Physiol Scand. 1998 Sep;164(1):117-8 [9777033.001]
  • [Cites] Neurourol Urodyn. 2002;21(6):558-65 [12382247.001]
  • [Cites] Prog Med Chem. 2003;41:167-94 [12774694.001]
  • [Cites] Cell Tissue Res. 2010 Nov;342(2):295-306 [20953633.001]
  • [Cites] Nature. 1967 May 6;214(5088):597-8 [6036174.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jun;293(3):939-45 [10869395.001]
  • [Cites] Br J Pharmacol. 2002 Jan;135(1):129-34 [11786488.001]
  • [Cites] J Urol. 2002 Sep;168(3):1247-52 [12187276.001]
  • [Cites] Eur J Pharmacol. 2005 Aug 22;518(2-3):195-202 [16054622.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119 [16465187.001]
  • [Cites] Br J Pharmacol. 1999 Feb;126(3):819-25 [10188996.001]
  • (PMID = 21221199.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3016425
  • [Keywords] NOTNLM ; Adrenergic beta-agonists / Afferent pathways / Urinary bladder, overactive
  •  go-up   go-down


38. Lindekleiv H, Skjaerpe PA, Due J: [Bladder stone surgery in antiquity]. Tidsskr Nor Laegeforen; 2007 Dec 13;127(24):3244-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder stone surgery in antiquity].
  • Bladder stone with subsequent urinary retention was a common and challenging disease up to the 19 th century, and still is in tropical countries.
  • If surgery was impossible, the urinary retention could be relieved with a catheter.
  • The surgical technique for bladder stone remained unchanged up to the 16 th century, and some of its principles are still employed in urology.
  • This article translates parts of Aulus Cornelius Celsus' treatise on bladder stone, found in his encyclopedia "De Medicina".
  • [MeSH-major] Urinary Bladder Calculi / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084381.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


39. Stein R, Wiesner C, Beetz R, Schwarz M, Thüroff JW: Urinary diversion in children and adolescents with neurogenic bladder: the Mainz experience. Part I: Bladder augmentation and bladder substitution--therapeutic algorisms. Pediatr Nephrol; 2005 Jul;20(7):920-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary diversion in children and adolescents with neurogenic bladder: the Mainz experience. Part I: Bladder augmentation and bladder substitution--therapeutic algorisms.
  • After the failure of conservative treatment of neurogenic bladders (deterioration of the upper urinary tract/incontinence), bladder augmentation/bladder substitution and supravesical urinary diversion have to be considered.
  • In our concept, bladder augmentation is indicated for hyperreflexive and small low compliance bladders with normal upper urinary tracts.
  • In patients with small and hyperreflexive bladders, high-grade reflux and/or dilatation of the upper tracts, bladder substitution and ureteral reimplantation are appropriate.
  • For patients with chronic renal failure, deterioration of the upper urinary tract and those who are not able to perform a self-catheterization of a continent stoma, colonic conduit diversion is our therapy of choice.
  • Of these, 24 received an orthotopic reservoir (bladder augmentation, n =10; combined with FS, n =1; orthotopic bladder substitution with ureteral reimplantation, n =14).
  • As compared to preoperatively, the upper urinary tracts remained stable or improved in all ten patients with bladder augmentation and in 20/23 renal units (RUs) with bladder substitution at the latest follow-up.
  • Eight of ten patients with bladder augmentation are continent.
  • All 13 patients with bladder substitution are continent during the day; one requires a safety pad at night.
  • Bladder augmentation has been effective in patients with hyperreflexive and small low compliance bladders and normal upper urinary tracts.
  • In those with high-grade reflux and/or dilatation of the upper tracts, bladder substitution and ureteral reimplantation are recommended.
  • [MeSH-major] Urinary Bladder, Neurogenic / surgery. Urinary Diversion. Urinary Reservoirs, Continent
  • [MeSH-minor] Acid-Base Equilibrium. Adolescent. Adult. Algorithms. Child. Child, Preschool. Female. Humans. Kidney / physiopathology. Kidney Transplantation. Male. Nephrectomy. Postoperative Period. Reoperation. Retrospective Studies. Ureter / surgery. Urinary Incontinence / etiology. Urinary Incontinence / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1996 Dec;156(6):2031-3 [8965337.001]
  • [Cites] J Urol. 2000 Jan;163(1):256-63 [10604371.001]
  • [Cites] J Urol. 1990 Aug;144(2 Pt 2):445-53; discussion 460 [2374218.001]
  • [Cites] J Urol. 1985 Oct;134(4):705-7 [4032574.001]
  • [Cites] J Urol. 1994 May;151(5):1193-7 [8158758.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 2):1096-8; discussion 1103 [9719284.001]
  • [Cites] Urology. 1998 Oct;52(4):672-8 [9763092.001]
  • [Cites] Dev Med Child Neurol. 1995 Jan;37(1):19-29 [7828784.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 2):699-703 [1640550.001]
  • [Cites] J Urol (Paris). 1990;96(2):93-6 [2341746.001]
  • [Cites] Arch Dis Child. 1992 May;67(5):640-1 [1599305.001]
  • [Cites] J Urol. 2002 Sep;168(3):1013-6; discussion 1016-7 [12187211.001]
  • [Cites] J Urol. 2001 May;165(5):1427-32 [11342891.001]
  • [Cites] Dev Med Child Neurol. 1990 Aug;32(8):698-706 [2210084.001]
  • [Cites] J Urol. 1993 Sep;150(3):835-7 [8345595.001]
  • [Cites] J Pediatr. 1995 Sep;127(3):368-72 [7658264.001]
  • [Cites] J Urol. 1995 Aug;154(2 Pt 2):769-70 [7609175.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 2):575-7; discussion 578-9 [1640525.001]
  • [Cites] J Urol. 2001 Mar;165(3):922-5 [11176515.001]
  • [Cites] J Urol. 2000 Feb;163(2):450-5 [10647652.001]
  • [Cites] J Urol. 1995 Oct;154(4):1500-4 [7658577.001]
  • [Cites] J Urol. 2000 Feb;163(2):568-73 [10647686.001]
  • [Cites] Am J Dis Child. 1992 Jul;146(7):840-3 [1496955.001]
  • (PMID = 15856321.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Mehta A, Bachmann G: Premenopausal women with sexual dysfunction: the need for a bladder function history. J Sex Med; 2008 Feb;5(2):407-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premenopausal women with sexual dysfunction: the need for a bladder function history.
  • INTRODUCTION: Despite the high prevalence of both female sexual problems and bladder dysfunction in the premenopausal population, sexual history forms used in primary care offices rarely include questions about the impact of bladder dysfunction on sexual health.
  • AIM: To provide a review of the literature that illustrates the relationship between bladder problems and sexual performance of premenopausal women.
  • MAIN OUTCOME MEASURES: To objectively support by a review of the literature the need for a complete bladder history in when evaluating premenopausal women with female sexual dysfunction.
  • METHODS: Pubmed was searched for all articles (from November 1980 to June 2007) that reported on the effect bladder dysfunction has on premenopausal female sexual function.
  • RESULTS: The scant literature available strongly suggested that bladder dysfunction is a contributor to sexual dysfunction and that this medical concern should be considered in all women, regardless of age who present with sexual complaints.
  • CONCLUSION: Further studies need to be conducted in order to solidify a direct causal relationship between bladder dysfunction and premenopausal female sexuality.
  • These studies should include a larger sample size, clearly defined types of sexual dysfunction and bladder dysfunction, and appropriate follow-up of patient responses using validated objective and subjective outcome modalities to confirm that the patient responses are factual.
  • [MeSH-major] Premenopause. Sexual Dysfunction, Physiological / etiology. Urinary Incontinence / diagnosis. Women's Health
  • [MeSH-minor] Female. Health Status. Humans. Medical History Taking / methods. Sexual Behavior. Urinary Incontinence, Stress / diagnosis. Urinary Incontinence, Urge / diagnosis


41. Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, Ganjei-Azar P, Manoharan M, Jorda M: P16 expression in squamous cell carcinomas of cervix and bladder. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):344-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16 expression in squamous cell carcinomas of cervix and bladder.
  • Occasionally, SCCs may involve both uterine cervix and urinary bladder.
  • DESIGN: We reviewed 74 SCCs, 38 (51%) from urinary bladder and 36 (49%) from uterine cervix obtained between 2003 and 2008.
  • Of the 38 cases of bladder carcinoma, 21 occurred in females and 17 in males.
  • Of the 38 SCCs of urinary bladder, 14 (37%) expressed p16 (8 males, 6 females).
  • (1) The majority of SCCs of uterine cervix express p16. (2) More than a third of urinary bladder SCCs express p16. (3) SCCs of urinary bladder express p16 independent of gender. (4) p16 immunohistochemical expression alone cannot be used to discriminate between SCCs arising from uterine cervix versus urinary bladder.


42. Yuan Z, Chen B, Ren H, Pan Y: On the possibility of time-lapse ultrahigh-resolution optical coherence tomography for bladder cancer grading. J Biomed Opt; 2009 Sep-Oct;14(5):050502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the possibility of time-lapse ultrahigh-resolution optical coherence tomography for bladder cancer grading.
  • It has been recently demonstrated that the cellular details of bladder epithelium embedded in speckle noise can be uncovered with time-lapse ultrahigh-resolution optical coherence tomography (TL-uOCT) by proper time-lapse frame averaging that takes advantage of cellular micromotion in fresh biological tissue ex vivo.
  • Here, spectral-domain 3-D TL-uOCT is reported to further improve the image fidelity, and new experimental evidence is presented to differentiate normal and cancerous nuclei of rodent bladder epithelia.
  • Results of animal cancer study reveal that despite a slight overestimation (e.g., <10%) of nuclear size (D(N)) to histological evaluation, TL-uOCT is capable of distinguishing normal (D(N) approximately 7 microm) and cancerous (e.g., high-grade D(N(") ) approximately 13 microm) urothelia, which may potentially be very useful for enhancing the diagnosis of nonpapillary bladder cancer.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):47-74 [14715057.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1178-81 [1957169.001]
  • [Cites] Opt Express. 2008 Jun 9;16(12):8406-20 [18545554.001]
  • [Cites] Opt Lett. 2007 Mar 1;32(5):503-5 [17392902.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):050504 [17994860.001]
  • [Cites] Nat Med. 1998 Jul;4(7):861-5 [9662382.001]
  • (PMID = 19895098.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK059265; United States / NIDDK NIH HHS / DK / R01DK059265
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2774970
  •  go-up   go-down


43. Ching BJ, Wittler L, Proske J, Yagnik G, Qi L, Draaken M, Reutter H, Gearhart JP, Ludwig M, Boyadjiev SA: p63 (TP73L) a key player in embryonic urogenital development with significant dysregulation in human bladder exstrophy tissue. Int J Mol Med; 2010 Dec;26(6):861-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 (TP73L) a key player in embryonic urogenital development with significant dysregulation in human bladder exstrophy tissue.
  • Human bladder exstrophy-epispadias complex (BEEC) comprises a spectrum of urogenital anomalies in which part or all of the distal urinary tract fails to close.
  • Among them a murine p63+/+ knockout model showed the full picture of classic exstrophy of the bladder and other urogenital defects within the BEEC spectrum.
  • In addition, p63 expression analysis was performed in human blood and bladder derived samples of 15 BEEC newborns accompanied by sequencing analysis of their genomic DNA.
  • In mouse embryos, p63 expression was detected at days 9.5-12.5 in the cloacal membrane and urethral epithelium, supporting its role in the morphogenesis of the external genitalia and the bladder.
  • Our findings strongly suggest that p63 is not only involved in embryonic formation of the urogenital and ventrocaudal anatomy but is also highly dysregulated in human BEEC bladder tissue.
  • [MeSH-major] Bladder Exstrophy / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Epispadias / metabolism. Gene Expression Regulation, Developmental. Humans. In Situ Hybridization. Lymphocytes / metabolism. Mice. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors. Urinary Bladder / embryology. Urinary Bladder / metabolism

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042780.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00052; United States / NIDCR NIH HHS / DE / R01 DE016886
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


44. Scélo G, Brennan P: The epidemiology of bladder and kidney cancer. Nat Clin Pract Urol; 2007 Apr;4(4):205-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of bladder and kidney cancer.
  • Bladder and kidney cancer together account for about 5% of cancers worldwide, and represent the 9th and 14th most common cancers in terms of absolute numbers, respectively.
  • A number of important occupational, lifestyle and genetic factors have been implicated in bladder carcinogenesis, which have greatly increased our understanding of this disease.
  • In some instances, identification of these factors has contributed to the prevention or reduction of exposure to bladder carcinogens.
  • In this article, we evaluate the epidemiology of bladder and kidney cancer and also discuss potential priorities for future research.
  • [MeSH-major] Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Combined Modality Therapy. Female. Global Health. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Sex Distribution. Survival Analysis


45. Mangar SA, Scurr E, Huddart RA, Sohaib SA, Horwich A, Dearnaley DP, Khoo VS: Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer. Radiother Oncol; 2007 Nov;85(2):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer.
  • AIM: To assess the feasibility of using cine-MR to study intra-fractional time-volume and volume-deformity patterns of the bladder during radiotherapy as initial methodology for Predictive Organ Localization (POLO).
  • METHODS: Nine patients receiving radiotherapy for localized muscle invasive bladder cancer were prospectively studied.
  • Each had an MR scan performed on an empty bladder using a T1 weighted cine sequence over a period of 20 min.
  • Absolute bladder volumes were then correlated with changes in bladder wall position.
  • RESULTS: The mean post void residual bladder volume prior to radiotherapy at time 0 was 113 cm(3) [SD 53] and this did not differ significantly during radiotherapy -106 cm [SD 40] (p=0.24, paired t-test analysis).
  • A linear relationship was observed for the rate bladder filling over a 20 min period, which did not significantly change on the cine-MR during radiotherapy (regression coefficient 2.1 vs 1.6, respectively, p=0.51).
  • The development of such predictive methodology may compensate for the need to use an isotropic CTV-PTV margin to simply cover bladder filling when using image-guided radiotherapy.
  • [MeSH-major] Magnetic Resonance Imaging, Cine. Urinary Bladder / anatomy & histology. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931728.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


46. Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ: Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther; 2006 Apr-Jun;2(2):52-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital.
  • INTRODUCTION AND PURPOSE: In gall bladder cancers, even after curative surgery, survivals are dismal and loco-regional failure accounts for 40-86%.
  • With an aim to evaluate the natural history of gall bladder cancers, role of radiation therapy (RT) and prognostication, a retrospective analysis was undertaken.
  • MATERIALS AND METHODS: Between 1991-2000, 60 patients with gall bladder cancer, treated with radical intent, were evaluated.
  • CONCLUSION: Gall bladder cancers are aggressive and lethal.
  • Early diagnosis and curative surgery, followed by appropriate adjuvant radiation therapy, may improve survivals, with no established consensus till date.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Surgical Procedures. Humans. India. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998675.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Koebnick C, Michaud D, Moore SC, Park Y, Hollenbeck A, Ballard-Barbash R, Schatzkin A, Leitzmann MF: Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev; 2008 May;17(5):1214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index, physical activity, and bladder cancer in a large prospective study.
  • Increased body size and lack of physical activity are associated with increased risk of several cancers, but the relations of body mass index (BMI) and physical activity to bladder cancer are poorly understood.
  • We investigated the associations between BMI, physical activity, and bladder cancer in the NIH-AARP Diet and Health Study, a prospective cohort of 471,760 U.S. men and women, followed from 1995 to 2003.
  • During 3,404,642 person-years of follow-up, we documented 1,719 incident cases of bladder cancer.
  • Compared with normal weight, obesity was associated with an up to 28% increased risk for bladder cancer.
  • The multivariate relative risks of bladder cancer for BMI values of 18.5 to 24.9 (reference), 25.0 to 29.9, 30.0 to 34.9, and >or=35 kg/m2 were 1.0, 1.15, 1.22, and 1.28 (95% confidence interval, 1.02-1.61; P trend = 0.028).
  • The association between BMI and bladder cancer was consistent among subgroups defined by gender, education, smoking status, and other potential effect modifiers.
  • In contrast, physical activity showed no statistically significant relation with bladder cancer.
  • After multivariate adjustment, including BMI, the relative risks of bladder cancer for increasing frequency of physical activity [0 (reference), <1, 1-2, 3-4, and >or=5 times a week] were 1.0, 0.85, 0.89, 0.91, and 0.87 (95% confidence interval, 0.74-1.02; P trend = 0.358), respectively.
  • In conclusion, these findings provide support for a modest adverse effect of adiposity on risk for bladder cancer.
  • In contrast, our results do not suggest a relation between physical activity and bladder cancer.
  • [MeSH-major] Body Mass Index. Motor Activity. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483344.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


48. Colegate-Stone TJ, Raymond T, Khot U, Dickinson IK, Parker MC: Laparoscopic management of iatrogenic bladder injury and bladder stone formation following laparoscopic inguinal herniorrhaphy. Hernia; 2008 Aug;12(4):429-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of iatrogenic bladder injury and bladder stone formation following laparoscopic inguinal herniorrhaphy.
  • METHOD AND RESULT: We report on a rare complication following laparoscopic inguinal herniorrhaphy of bladder stone formation and its management.
  • CONCLUSION: To our knowledge a combined laparoscopic repair of the urinary bladder wall, following iatrogenic injury by a mesh fixation clip and retrieval of bladder stone (induced through the misplacement of the clip) has not been described previously.
  • [MeSH-major] Hernia, Inguinal / surgery. Laparoscopy / adverse effects. Prosthesis Implantation / adverse effects. Suture Techniques / adverse effects. Urinary Bladder / injuries. Urinary Bladder Calculi / etiology
  • [MeSH-minor] Adult. Cystoscopy. Device Removal / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Iatrogenic Disease. Surgical Mesh. Tomography, X-Ray Computed. Urologic Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 1993 May-Jun;7(3):155-8 [8503070.001]
  • [Cites] Surgery. 1996 Jan;119(1):110-1 [8560374.001]
  • [Cites] Br J Surg. 2006 Sep;93(9):1060-8 [16862612.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):221-7 [14625733.001]
  • [Cites] Am J Surg. 1994 Sep;168(3):275-9 [8080067.001]
  • [Cites] Br J Surg. 1986 Feb;73(2):123-4 [3947903.001]
  • (PMID = 18196444.001).
  • [ISSN] 1265-4906
  • [Journal-full-title] Hernia : the journal of hernias and abdominal wall surgery
  • [ISO-abbreviation] Hernia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


49. Mohammed A, Khan Z, Zamora I, Bhatti A: Biological markers in the diagnosis of recurrent bladder cancer: an overview. Expert Rev Mol Diagn; 2008 Jan;8(1):63-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological markers in the diagnosis of recurrent bladder cancer: an overview.
  • Over the last years, many biological markers emerged that act as an adjunct for the detection of early bladder cancer recurrence.
  • In this article, we give an overview on the biological markers that can play a role in early bladder cancer detection and can perhaps subsequently reduce the need for frequent cystoscopies.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088231.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 65
  •  go-up   go-down


50. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M: Antitumor effect of ascorbic acid, lysine, proline, arginine, and green tea extract on bladder cancer cell line T-24. Int J Urol; 2006 Apr;13(4):415-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effect of ascorbic acid, lysine, proline, arginine, and green tea extract on bladder cancer cell line T-24.
  • AIMS: Bladder cancer, the fourth highest incident cancer in men and tenth in women, is associated with a high rate of recurrence, even when treated in situ, and prognosis is poor once the cancer metastasizes to distant sites.
  • Based on anticancer properties, we investigated the effect of a mixture of lysine, proline, arginine, ascorbic acid, and green tea extract on human bladder cancer cells T-24 by measuring: proliferation, matrix metalloproteinase (MMP) expression, and cancer cell invasive potential.
  • METHODS: Human bladder cancer cells T-24 (ATCC) were grown in McCoy medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 mg/mL) in 24-well tissue culture plates.
  • The nutrient mixture significantly reduced the invasion of human bladder cancer cells T-24 through Matrigel in a dose-dependent fashion, with 95% inhibition at 500 microg/mL and 100% at 1000 microg/mL nutrient mixture (P < 0.001).
  • CONCLUSION: Our results suggest that our nutrient mixture is an excellent candidate for therapeutic use in the treatment of bladder cancer, by inhibiting critical steps in cancer development and spread, such as MMP secretion and invasion.
  • [MeSH-major] Antioxidants / therapeutic use. Arginine / therapeutic use. Ascorbic Acid / therapeutic use. Lysine / therapeutic use. Plant Extracts / therapeutic use. Proline / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Camellia sinensis. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Progression. Female. Humans. In Vitro Techniques. Male. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734861.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Plant Extracts; 0 / green tea extract AR25; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; K3Z4F929H6 / Lysine; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


51. Kakuta Y, Katoh T, Saitoh J, Yazawa K, Hosomi M, Itoh K: [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy]. Hinyokika Kiyo; 2006 Dec;52(12):951-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
  • Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the bladder is a rare disease, and the most effective therapeutic procedure remains unknown.
  • We report a case of primary MALT lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy (R-CHOP).
  • Computed tomography (CT) showed a solitary mass at the bladder.
  • Histological diagnosis of the tissue obtained by transurethral biopsy was extranodal marginal zone B cell lymphoma of MALT.
  • This is the fourteenth case of MALT lymphoma of the bladder in Japan.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell, Marginal Zone / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252980.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


52. Coenen MJ, Ploeg M, Schijvenaars MM, Cornel EB, Karthaus HF, Scheffer H, Witjes JA, Franke B, Kiemeney LA: Allelic imbalance analysis using a single-nucleotide polymorphism microarray for the detection of bladder cancer recurrence. Clin Cancer Res; 2008 Dec 15;14(24):8198-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance analysis using a single-nucleotide polymorphism microarray for the detection of bladder cancer recurrence.
  • PURPOSE: Non-muscle-invasive bladder cancer is a frequently occurring cancer, with an extremely high recurrence risk.
  • We investigated whether this method is suitable to detect allelic imbalance as an indicator of recurrences in non-muscle-invasive bladder cancer follow-up.
  • RESULTS: Urine samples with tumor showed allelic imbalance at 0.4% of all informative SNPs.
  • In samples without tumors, 0.04% of these SNPs were affected (P = 0.07).
  • In addition, Copy Number Analyser for GeneChip analysis showed more copy number changes in samples with a tumor (P = 0.001).
  • Losses and gains of chromosomal regions showed clustering, overlapping with known bladder cancer loci.
  • However, 25 (22%) patients with a tumor recurrence did not display any regions with copy number changes, whereas 24 (53%) individuals without a recurrence did.
  • CONCLUSION: Single-nucleotide polymorphism microarray analysis of allelic imbalance in urine cannot replace urethrocystoscopy and cytology for the detection of recurrences in non-muscle-invasive bladder cancer follow-up.
  • [MeSH-major] Allelic Imbalance / genetics. Neoplasm Recurrence, Local / diagnosis. Oligonucleotide Array Sequence Analysis / methods. Polymorphism, Single Nucleotide. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088036.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Coyne KS, Matza LS, Kopp Z, Abrams P: The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol; 2006 Jun;49(6):1079-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
  • OBJECTIVES: The purpose of this study was to evaluate the validity and responsiveness of a global measure for overactive bladder (OAB), the Patient Perception of Bladder Condition (PPBC).
  • In addition to the PPBC, patients completed two condition-specific health-related quality of life (HRQL) measures, the Overactive Bladder Questionnaire (OAB-q) and King's Health Questionnaire (KHQ), and bladder diaries at baseline and 12 wk.
  • Significant correlations were present at baseline and among change scores between the PPBC and the bladder diaries (p < 0.001), OAB-q (p < 0.001), and KHQ (p < 0.01).
  • CONCLUSION: The PPBC, a global patient-reported measure of bladder condition, demonstrated good construct validity and responsiveness to change.
  • These findings support the use of the PPBC as a global assessment of bladder condition among patients with OAB.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder, Overactive / diagnosis

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16460875.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Anumanthan G, Makari JH, Honea L, Thomas JC, Wills ML, Bhowmick NA, Adams MC, Hayward SW, Matusik RJ, Brock JW 3rd, Pope JC 4th: Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. J Urol; 2008 Oct;180(4 Suppl):1778-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium.
  • PURPOSE: We have previously reported that embryonic rat bladder mesenchyma has the appropriate inductive signals to direct pluripotent mouse embryonic stem cells toward endodermal derived urothelium and develop mature bladder tissue.
  • Heterospecific recombinant xenografts were created by combining the embryonic rat bladder mesenchyma shells with mesenchymal stem cells and grafting them into the renal subcapsular space of athymic nude mice.
  • RESULTS: Histological examination of xenografts comprising mouse mesenchymal stem cells and rat embryonic rat bladder mesenchyma yielded mature bladder structures showing normal microscopic architecture as well as proteins confirming functional characteristics.
  • These differentiated bladder structures demonstrated appropriate alpha-smooth muscle actin staining.
  • CONCLUSIONS: In the appropriate signaling environment bone marrow derived mesenchymal stem cells can undergo directed differentiation toward endodermal derived urothelium and develop into mature bladder tissue in a tissue recombination model.
  • This model serves as an important tool for the study of bladder development with long-term application toward cell replacement therapies in the future.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721942.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068593; United States / NIDDK NIH HHS / DK / R01-DK057483
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS767702; NLM/ PMC4802964
  •  go-up   go-down


55. Ho CC, Khandasamy Y, Singam P, Hong Goh E, Zainuddin ZM: Encrusted and incarcerated urinary bladder catheter: what are the options? Libyan J Med; 2010 Nov 25;5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encrusted and incarcerated urinary bladder catheter: what are the options?
  • Urinary bladder catheter encrustations are known complications of long-term urinary catheterisation, which is commonly seen in clinical practice.
  • The options in managing an encrusted and incarcerated urinary bladder catheter include extracorporeal shock wave lithotripsy and lithoclast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 1999 May;83(7):770-5 [10368194.001]
  • [Cites] J Urol. 1999 Dec;162(6):2058-60 [10569569.001]
  • [Cites] World J Urol. 1999 Dec;17(6):345-50 [10654364.001]
  • [Cites] J Am Board Fam Pract. 2000 Mar-Apr;13(2):116-9 [10764193.001]
  • [Cites] Urol Res. 1993;21(6):407-11 [8171763.001]
  • [Cites] J Clin Epidemiol. 1989;42(9):835-42 [2778465.001]
  • [Cites] J Clin Microbiol. 1987 Nov;25(11):2216-7 [3320089.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):649-52 [9832268.001]
  • [Cites] Urol Res. 1989;17(6):349-52 [2560278.001]
  • [Cites] Am J Med. 1991 Sep 16;91(3B):65S-71S [1928194.001]
  • (PMID = 21483557.001).
  • [ISSN] 1819-6357
  • [Journal-full-title] The Libyan journal of medicine
  • [ISO-abbreviation] Libyan J Med
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3066753
  • [Keywords] NOTNLM ; bladder / catheter / complications / encrustations / incarcerated / stuck / urinary
  •  go-up   go-down


56. Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A: Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics; 2010 Jun;9(6):1324-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomics analysis of bladder cancer exosomes.
  • Ex vivo analysis of exosomes may provide biomarker discovery platforms and form non-invasive tools for disease diagnosis and monitoring.
  • These vesicles have never before been studied in the context of bladder cancer, a major malignancy of the urological tract.
  • We present the first proteomics analysis of bladder cancer cell exosomes.
  • Using ultracentrifugation on a sucrose cushion, exosomes were highly purified from cultured HT1376 bladder cancer cells and verified as low in contaminants by Western blotting and flow cytometry of exosome-coated beads.
  • Interrogating the Gene Ontology database highlighted a strong association of this proteome with carcinoma of bladder and other sites.
  • Some were confirmed positive on urinary exosomes from a bladder cancer patient.
  • [MeSH-major] Exosomes / metabolism. Proteomics / methods. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Amino Acid Sequence. Blotting, Western. Cell Line, Tumor. Chromatography, Liquid. Databases, Genetic. Electrophoresis, Gel, Two-Dimensional. Flow Cytometry. Histocompatibility Antigens Class I / immunology. Humans. Molecular Sequence Data. Nanotechnology. Neoplasm Proteins / chemistry. Neoplasm Proteins / urine. Reproducibility of Results. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Immunol. 2005 Jul;17(7):879-87 [15908444.001]
  • [Cites] Biol Reprod. 2005 Jun;72(6):1452-65 [15635128.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3631-8 [16046478.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7554-63 [16243831.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1534-42 [16424182.001]
  • [Cites] Mol Cell Neurosci. 2006 Apr;31(4):642-8 [16446100.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):921-7 [16953238.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1847-57 [17021608.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3809-14 [17133577.001]
  • [Cites] Nat Cell Biol. 2007 Jun;9(6):654-9 [17486113.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1969-78 [17641064.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7458-66 [17671216.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4646-55 [17956143.001]
  • [Cites] Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22 [18228490.001]
  • [Cites] Mol Immunol. 2008 Apr;45(8):2343-51 [18192019.001]
  • [Cites] Mol Ther. 2008 Apr;16(4):782-90 [18362931.001]
  • [Cites] J Proteome Res. 2008 May;7(5):2088-96 [18373357.001]
  • [Cites] J Immunol Methods. 2008 Jun 1;335(1-2):98-105 [18423480.001]
  • [Cites] Biol Pharm Bull. 2008 Jun;31(6):1059-62 [18520029.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):13-21 [18589210.001]
  • [Cites] Proteomics. 2008 Oct;8(19):3924-32 [18763712.001]
  • [Cites] J Transl Med. 2009;7:4 [19138409.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):363-79 [19056867.001]
  • [Cites] Clin Lung Cancer. 2009 Jan;10(1):42-6 [19289371.001]
  • [Cites] J Proteome Res. 2008 Dec;7(12):5157-66 [19367702.001]
  • [Cites] FASEB J. 2009 May;23(5):1541-57 [19109410.001]
  • [Cites] Br J Cancer. 2009 May 19;100(10):1603-7 [19401683.001]
  • [Cites] Br J Cancer. 2009 May 19;100(10):1608-16 [19401687.001]
  • [Cites] FASEB J. 2009 Jun;23(6):1858-68 [19190083.001]
  • [Cites] Expert Rev Proteomics. 2009 Jun;6(3):267-83 [19489699.001]
  • [Cites] Mol Cell Proteomics. 2009 Jun;8(6):1192-205 [19204029.001]
  • [Cites] J Proteome Res. 2009 Mar;8(3):1304-14 [19199708.001]
  • [Cites] Nat Rev Immunol. 2009 Aug;9(8):581-93 [19498381.001]
  • [Cites] Proteomics. 2009 Nov;9(21):4997-5000 [19810033.001]
  • [Cites] Mol Cell Proteomics. 2010 Feb;9(2):197-208 [19837982.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7309-18 [11390481.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):337-49 [11487543.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):295-305 [12147373.001]
  • [Cites] J Immunol Methods. 2002 Dec 15;270(2):211-26 [12379326.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):522-31 [12645951.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):10963-72 [12519789.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1807-15 [15111327.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Jul;31(1):114-21 [14975938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73 [15326289.001]
  • [Cites] J Natl Cancer Inst. 1977 Apr;58(4):881-90 [191628.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3630-6 [3708594.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1161-72 [8642258.001]
  • [Cites] Histol Histopathol. 1999 Apr;14(2):657-64 [10212826.001]
  • [Cites] Proteomics. 2004 Dec;4(12):4019-31 [15478216.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2237-43 [16081791.001]
  • (PMID = 20224111.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2877990
  •  go-up   go-down


57. Bozios G, Capizzello A, Tsekeris P: External beam radiotherapy of bladder carcinoma: considerations in determining the irradiation field margins. J BUON; 2010 Jul-Sep;15(3):489-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiotherapy of bladder carcinoma: considerations in determining the irradiation field margins.
  • PURPOSE: Motions of the bladder and rectum during pelvic irradiation are considered as major causes of geometrical uncertainties.
  • The aim of this study was, firstly, to determine these margins, comparing series of CT scans, performed at simulation time, with empty (EB) and full bladder (FB) and, secondly, to evaluate the dose volume histograms (DVHs) of tumor and rectum using standard treatment margins.
  • METHODS: Fifteen patients with muscle-invading urinary bladder carcinoma underwent two scan series with EB and FB bladder during radiotherapy (RT) simulation.
  • Gross tumor volume (GTV), clinical target volume (CTV), planning treatment volume (PTV) and organs at risk (OAR) were contoured.
  • Displacements of the bladder wall were determined at all directions.
  • RESULTS: The mean bladder volume was 119.3±55.9 cm3 and 264.3±145.7 cm3 for EB and FB CT series, respectively (p<0.001).
  • The maximum bladder wall displacement was observed at cranial direction (2.2±0.6 cm for the EB vs. 3.4±1.0 cm for the FB series; p<0.001) and at caudal direction (2.3±0.6 cm for the EB vs. 3.6±1.0 cm for the FB series; p<0.001).
  • Standard anisotropic margins of 2 cm in craniocaudal and posterior-anterior directions and 1.2 cm in lateral direction gave coverage to 75% of all bladder movements caused by FB.
  • Analysis of DVHs and tumor control probability (TCP) calculations gave same results (74%), while normal tissue complication probability (NTCP) of the rectum showed no significant changes.
  • CONCLUSION: CT scans series with empty and full bladder, performed at simulation time, could offer a potential advantage to evaluate the target expansion necessary to cover the bladder wall for each patient, giving more information about safe margining.
  • [MeSH-major] Radiotherapy Planning, Computer-Assisted / methods. Urinary Bladder Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941815.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


58. Masuda N, Hayashi Y, Matsuyoshi H, Chancellor MB, de Groat WC, Yoshimura N: Characterization of hyperpolarization-activated current (Ih) in dorsal root ganglion neurons innervating rat urinary bladder. Brain Res; 2006 Jun 22;1096(1):40-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of hyperpolarization-activated current (Ih) in dorsal root ganglion neurons innervating rat urinary bladder.
  • Afferent pathways innervating the urinary bladder consist of myelinated Adelta-fibers and unmyelinated C-fibers.
  • Normal voiding is dependent on mechanoceptive Adelta-fiber bladder afferents that respond to bladder distention.
  • However, the mechanisms for controlling the excitability of Adelta-fiber bladder afferents are not fully understood.
  • We therefore used whole cell patch-clamp techniques to investigate the properties of hyperpolarization-activated, cyclic nucleotide-gated (HCN) currents (I(h)) in dorsal root ganglion (DRG) neurons innervating the urinary bladder of rats.
  • The neurons were identified by axonal tracing with a fluorescent dye, Fast Blue, injected into the bladder wall.
  • Hyperpolarizing voltage step pulses from -40 to -130 mV produced voltage- and time-dependent inward I(h) currents in bladder afferent neurons.
  • The amplitude and current density of I(h) at a holding potential of -130 mV was significantly larger in medium-sized bladder afferent neurons (diameter: 37.8 +/- 0.3 microm), a small portion (19%) of which were sensitive to capsaicin (1 microM), than in uniformly capsaicin-sensitive small-sized (27.6 +/- 0.5 microm) bladder neurons.
  • In medium-sized bladder neurons, a selective HCN channel inhibitor, ZD7288, dose-dependently inhibited I(h) currents.
  • These results indicate that I(h) currents are predominantly expressed in medium-sized bladder afferent neurons innervating the bladder and that inhibition of I(h) currents delayed recovery from the spike after-hyperpolarization.
  • Thus, it is assumed that I(h) currents could control excitability of mechanoceptive Adelta-fiber bladder afferent neurons, which are usually capsaicin-insensitive and larger in size than capsaicin-sensitive C-fiber bladder afferent neurons.
  • [MeSH-major] Ganglia, Spinal / metabolism. Neurons / metabolism. Potassium Channels / metabolism. Urinary Bladder / innervation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPSAICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765328.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 57267; United States / NIDDK NIH HHS / DK / DK 68557; United States / NICHD NIH HHS / HD / P01 HD39768
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Potassium Channels; 0 / Pyrimidines; 133059-99-1 / ICI D2788; S07O44R1ZM / Capsaicin
  •  go-up   go-down


59. Karim T, Topno M, Sharma V, Picardo R, Hastir A: Bladder injuries frequently missed in polytrauma patients. Open Access J Urol; 2010;2:63-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder injuries frequently missed in polytrauma patients.
  • Bladder injuries are very common in patients who have had road traffic accidents.
  • The method of diagnosis and management of such injuries is well established and accepted.
  • However, trauma to the bladder can be associated with other life-threatening injuries which are frequently missed, and often diagnosed during laparotomy for other reasons.
  • The aim of this study was to diagnose bladder injury in polytrauma patients as early as possible, taking into consideration the fact that these patients are hemodynamically unstable and require rapid evaluation and management.
  • In order to achieve our objective, we used bedside sonography with retrograde instillation of normal saline to diagnose bladder injury in addition to use of the conventional retrograde cystogram.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24198615.001).
  • [ISSN] 1179-1551
  • [Journal-full-title] Open access journal of urology
  • [ISO-abbreviation] Open Access J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3818878
  • [Keywords] NOTNLM ; bladder injury / bladder rupture / retrograde cystogram
  •  go-up   go-down


60. Kennedy C, Tasker PN, Gallacher G, Westfall TD: Identification of atropine- and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder. J Neurosci; 2007 Jan 24;27(4):845-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of atropine- and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder.
  • We used P2X1 receptor antagonists to further characterize the purinergic component of neurotransmission in isolated detrusor muscle of guinea pig urinary bladder.
  • PPADS (100 microM) and suramin (300 microM) reduced the peak neurogenic contraction of the mouse urinary bladder to 30-40% of control.
  • Thus, P2X1 receptor antagonists inhibit, but do not abolish, the noncholinergic component of neurogenic contractions of guinea pig and mouse urinary bladder, indicating a second mode of action of neuronally released ATP.
  • This has important implications for treatment of dysfunctional urinary bladder, for which this atropine- and P2X1 antagonist-resistant site represents a novel therapeutic target.
  • [MeSH-major] Atropine / antagonists & inhibitors. Muscle Contraction / physiology. Purinergic P2 Receptor Antagonists. Pyridoxal Phosphate / analogs & derivatives. Urinary Bladder / physiology. Urinary Bladder, Neurogenic / physiopathology

  • Hazardous Substances Data Bank. ATROPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251425.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Purinergic P2 Receptor Antagonists; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X; 149017-66-3 / pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; 5V5IOJ8338 / Pyridoxal Phosphate; 6032D45BEM / Suramin; 7C0697DR9I / Atropine
  •  go-up   go-down


61. Powell CR, Kreder KJ: Treatment of bladder diverticula, impaired detrusor contractility, and low bladder compliance. Urol Clin North Am; 2009 Nov;36(4):511-25, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bladder diverticula, impaired detrusor contractility, and low bladder compliance.
  • Bladder diverticula are common enough to be encountered by most urologists in practice but are reported less frequently in the literature than they were 50 years ago.
  • Some patients can be managed nonoperatively, whereas others will need surgical intervention consisting of bladder outlet reduction and possibly removal of the diverticulum itself.
  • Many new techniques for treatment of the bladder outlet and the diverticulum are available, such as laparoscopy and robotic surgery.
  • [MeSH-major] Diverticulum / diagnosis. Diverticulum / physiopathology. Diverticulum / therapy. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / physiopathology. Urinary Bladder Diseases / therapy

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942049.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 62
  •  go-up   go-down


62. Olbert PJ, Schrader AJ, Simon C, Dalpke A, Barth P, Hofmann R, Hegele A: In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Res; 2009 Jun;29(6):2067-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
  • The purpose of this study was to examine the local effects of CpG-ODN on the murine bladder wall after intravesical instillation and the effects on cytokine expression in an orthotopic murine bladder cancer model.
  • MATERIALS AND METHODS: Histopathology, immunohistochemistry and fluorescence microscopy were performed after different instillation schedules of stimulatory, non-stimulatory biotinylized and FITC-labelled CpG-ODN into the murine bladder.
  • MB-49 murine bladder cancer cells were tested for TLR-9 expression to exclude a potential direct responsiveness to CpG-ODN.
  • Furthermore induction of apoptosis was tested by annexin V staining and FACS analysis of CpG-ODN stimulated tumor cells.
  • In an orthotopic C57/Bl6 murine bladder cancer model, the expressions of IL-12, IFNgamma, IL-10 and TGF-beta were evaluated after repeated CpG-ODN treatment.
  • Bladder submucosa stained positive for biotin.
  • FITC-labelled ODN adhered to the bladder mucosa and penetration of the mucosal barrier was not detected.
  • Repeated intravesical instillations of CpG-ODN in orthotopic murine tumor bearing urinary bladders resulted in significant up-regulation of both Th-1 and Th-2 cytokines.
  • They exert a pronounced immunological response both in the native murine urinary bladder and in murine TCC.
  • The mechanisms of action appear to be mediated immunologically, There was no direct effect of CpG-ODN on the tumor cells in this model.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Carcinoma, Transitional Cell / therapy. Oligodeoxyribonucleotides / therapeutic use. Urinary Bladder / physiology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Animals. Apoptosis. Female. Immunoenzyme Techniques. In Vitro Techniques. Interferon-gamma / genetics. Interferon-gamma / metabolism. Interleukin-10 / genetics. Interleukin-10 / metabolism. Interleukin-12 / genetics. Interleukin-12 / metabolism. Mice. Mice, Inbred C3H. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Toll-Like Receptor 9 / genetics. Toll-Like Receptor 9 / metabolism. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / CPG-oligonucleotide; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Tlr9 protein, mouse; 0 / Toll-Like Receptor 9; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


63. Neĭmark AI, Klyzhina EA, Neĭmark BA: [Effects of various kinds of conservative treatment on urodynamics and microcirculation in females with hyperactive urinary bladder]. Urologiia; 2006 Nov-Dec;(6):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of various kinds of conservative treatment on urodynamics and microcirculation in females with hyperactive urinary bladder].
  • Urodynamic and microcirculatory parameters were studied in 70 females aged from 21 to 70 years with hyperactive urinary bladder (HAUB) and 15 females free of diseases of the lower urinary tract.
  • HAUB patients appeared to develop microcirculatory disorders in the wall of the bladder manifest as slow circulation resulting in detrusor hyperactivity responsible for HAUB symptoms.
  • HAUB development is accompanied with urodynamic disorders - enhancement of detrusor contractility and that of urethral sphincter with growing amplitude of their electric activity leading to potentiation of bladder evacuatory ability.
  • [MeSH-major] Urinary Bladder / blood supply. Urinary Bladder, Overactive / therapy. Urodynamics

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315717.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


64. Eandi JA, Asuncion A, Vandewalker KN, Javidan J: Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma. Int J Urol; 2007 Sep;14(9):862-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma.
  • Granular cell tumor of the bladder is exceptionally rare, with only 11 cases reported in the published reports.
  • Pseudoepitheliomatous hyperplasia of the overlying squamous epithelium has been observed in non-bladder granular cell tumors.
  • We herein report the first case of bladder granular cell tumor to exhibit pseudoepitheliomatous hyperplasia.
  • This phenomenon is significant as it may potentially lead to difficulty in the distinction between infiltrative squamous cell carcinoma and pseudoepitheliomatous hyperplasia in cases of granular cell tumor of the bladder.
  • This case also represents the first granular cell tumor to demonstrate colocalization with adenocarcinoma of the bladder.
  • Based on our findings and a review of the published reports, management for granular cell tumor of the bladder should involve a course of local resection combined with active surveillance given its typical benign course, albeit with the potential for local recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Granular Cell Tumor / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760758.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


65. Fierabracci A, Caione P, Di Giovine M, Zavaglia D, Bottazzo GF: Identification and characterization of adult stem/progenitor cells in the human bladder (bladder spheroids): perspectives of application in pediatric surgery. Pediatr Surg Int; 2007 Sep;23(9):837-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of adult stem/progenitor cells in the human bladder (bladder spheroids): perspectives of application in pediatric surgery.
  • The aim of this study was to isolate stem/progenitor cells from the human bladder.
  • We have devised a method for isolating stem/progenitor cells from the human bladder.
  • This is based on the enzymatic digestion of fresh surgical bladder specimens, followed by culture of cells in the presence of EGF and bFGF.
  • Spheroids with self-replicative potential were obtained from all bladder specimens.
  • These spheroids represent a predominant functional type of stem/progenitor cells within the human bladder.
  • [MeSH-major] Adult Stem Cells / cytology. Urinary Bladder / cytology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2004 Nov 20-26;364(9448):1872-83 [15555667.001]
  • [Cites] Cell. 2000 Jan 7;100(1):157-68 [10647940.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2412-22 [11588038.001]
  • [Cites] BMJ. 2002 Aug 17;325(7360):372-6 [12183311.001]
  • [Cites] J Neurosci. 2002 Jan 15;22(2):437-45 [11784788.001]
  • [Cites] Cell. 2001 Jun 29;105(7):829-41 [11439179.001]
  • [Cites] Circ Res. 2004 Oct 29;95(9):911-21 [15472116.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):688-94 [12700753.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):570-82 [12904523.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] Circ Res. 2003 Apr 4;92(6):598-608 [12676811.001]
  • (PMID = 17619197.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 62229-50-9 / Epidermal Growth Factor; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


66. Housset M, Durdux C, Thariat J, Dufour B: [Chemoradiation in bladder cancer]. Bull Cancer; 2010;97 Suppl Cancer de la vessie:19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiation in bladder cancer].
  • [Transliterated title] Chimioradiothérapie concomitante des carcinomes de la vessie.
  • Bladder cancer is the second most common urologic tumor after prostate cancer.
  • Radical cystectomy is the standard treatment of localized muscle-invasive tumors.
  • However, urinary diversion (using a conduit or continent diversion) following radical cystectomy can be debilitating.
  • This review summarizes the main published series of radiochemotherapy in invasive bladder cancer.
  • Results for local control, survivals, bladder preservation rates and toxicity are presented.
  • [MeSH-major] Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534386.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


67. Halimi M, Salehi A, Baybordi H, Nezami N: Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):155-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma.
  • BACKGROUND: Molecular genetics and immunopathologic analysis of bladder cancer have shown some abnormalities in a number of genes and proteins that have been implicated in the development and progression of such tumors, mainly in the p53 pathway.
  • AIMS: To investigate the rate of positively stained p53 protein in patients with urothelial papillary carcinoma of the bladder (UCB) by immunohistochemistry and its relationship with tumor grade, gender and age of the patients.
  • SETTINGS AND DESIGN: During the present cross-sectional study, 100 paraffin-embedded specimens of UCB, which were provided from biopsies of the bladder by transurethral access, were immunohistochemically stained and studied for p53 protein from May 2006 to May 2007 in our referral center pathology laboratory.
  • This rate was significantly higher in females (10/29 vs. 1/71; P < 0.001; odds ratio [OR]: 0.23; 95% confidence interval [CI]: 4.43-306.08), patients with 70 or older than 70 years (8/42 vs. 3/58; P = 0.04; OR: 0.55; 95% CI: 1.07-17.39) and in high-grade tumors (10/58 vs. 1/42; P = 0.02; OR: 0.59; 95% CI: 0.01-0.95).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carcinoma, Transitional Cell / pathology. Tumor Suppressor Protein p53 / analysis. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Cross-Sectional Studies. Female. Humans. Male. Microtomy. Middle Aged. Predictive Value of Tests. Severity of Illness Index. Sex Factors. Staining and Labeling. Urinary Bladder / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332900.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


68. Chang HR, Huang HP, Kao YL, Chen SL, Wu SW, Hung TW, Lian JD, Wang CJ: The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells. Chem Biol Interact; 2010 Jan 5;183(1):172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells.
  • Surgical specimens of tumorous and non-tumorous bladder tissues were collected from 12 patients with bladder cancer.
  • Increased expressions of Ras, RhoA, Akt, PI-3K were demonstrated in the tumors as compared to adjacent control tissues.
  • To understand the impact of Ras over-expression on bladder cancer progression, human bladder cancer TSGH 8301 cells were transfected with Ras DNA.
  • Our results provide evidence that Ras-induced RhoA and NF-kappaB activation was involved in the invasion/migration of bladder cancer.
  • Through Ras and/or RhoA inhibition, there might be an opportunity for new therapeutic interventions in bladder cancer.
  • [MeSH-major] Amides / pharmacology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. Urinary Bladder Neoplasms / metabolism. ras Proteins / metabolism. rho-Associated Kinases / antagonists & inhibitors. rhoA GTP-Binding Protein / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Cytoskeleton. Female. Humans. Male. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Middle Aged. NF-kappa B / metabolism. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Transfection

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896475.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amides; 0 / NF-kappa B; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / rho-Associated Kinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / ras Proteins; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


69. Mitterberger M, Pinggera GM, Neuwirt H, Maier E, Akkad T, Strasser H, Gradl J, Pallwein L, Bartsch G, Frauscher F: Three-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuria. BJU Int; 2007 Jan;99(1):111-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuria.
  • OBJECTIVE: To assess the value of three-dimensional (3D) vs two-dimensional (2D) ultrasonography (US) in the diagnostic evaluation of the urinary bladder in patients with haematuria.
  • Mountain View, CA, USA) and the Perspective(R) 3D technique, to assess the presence of bladder lesions, including bladder cancer, bladder wall hypertrophy with trabeculation and diverticula, mucosal bladder folds or re-growth of the prostate mimicking a bladder tumour.
  • The imaging findings were compared with cystoscopy and/or bladder biopsy.
  • RESULTS: In 21 of the 42 patients (50%) cystoscopy with bladder biopsy revealed bladder cancer.
  • Overall, 3D-US gave a correct diagnosis for 36 of 42 patients (86%).
  • All 21 bladder cancers were correctly diagnosed, and 15 (71%) of the 21 benign bladder lesions were correctly identified.
  • By contrast, 2D-US findings gave suspected bladder cancer in all patients.
  • Thus, this diagnostic technique might be useful for routine evaluation of the urinary bladder.
  • [MeSH-major] Hematuria / ultrasonography. Imaging, Three-Dimensional / instrumentation. Urinary Bladder Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034493.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Maheshwari PN, Bhandarkar DS, Shah RS: Laparoscopic repair of idiopathic perforation of urinary bladder. Surg Laparosc Endosc Percutan Tech; 2005 Aug;15(4):246-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic repair of idiopathic perforation of urinary bladder.
  • In view of high creatinine level, normal kidneys, and acute-onset moderate ascites, urinary ascites was suspected.
  • Cystoscopy identified a 2.5-cm perforation on the right side of the dome of the bladder.
  • This case highlights the successful use of laparoscopy in the treatment of a rare urological condition and reviews the previously reported cases of laparoscopic closure of bladder perforation.
  • [MeSH-major] Laparoscopy. Urinary Bladder / injuries. Urinary Bladder / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082317.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


72. Reitz A, Haferkamp A, Wagener N, Gerner HJ, Hohenfellner M: Neurogenic bladder dysfunction in patients with neoplastic spinal cord compression: adaptation of the bladder management strategy to the underlying disease. NeuroRehabilitation; 2006;21(1):65-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenic bladder dysfunction in patients with neoplastic spinal cord compression: adaptation of the bladder management strategy to the underlying disease.
  • OBJECTIVES: To study the outcome of different bladder management strategies in patients with neoplastic spinal cord compression.
  • According to the urodynamic data and the underlying disease different bladder management strategies were recommended.
  • In patients with curatively treated disease a full bladder rehabilitation program was arranged.
  • At follow-up, all patients had successfully finished bladder rehabilitation program and at follow up, all patients were continuing their previously recommended bladder rehabilitation program.
  • CONCLUSION: Underlying disease and life expectancy should be considered for the selection of bladder management in patients with neoplastic spinal cord compression.
  • In patients with curatively treated disease, a full bladder rehabilitation program is recommended while in patients with malignant disease and palliative care, a suprapubic catheter might be the treatment of choice.
  • [MeSH-major] Spinal Cord Compression / complications. Spinal Cord Neoplasms / complications. Urinary Bladder, Neurogenic / etiology. Urinary Bladder, Neurogenic / rehabilitation. Urinary Catheterization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720939.001).
  • [ISSN] 1053-8135
  • [Journal-full-title] NeuroRehabilitation
  • [ISO-abbreviation] NeuroRehabilitation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Muscarinic Antagonists
  •  go-up   go-down


73. Fujimoto K, Matsumura Y, Tani Y, Ozono S, Hirao Y, Okajima E: Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue. Int J Urol; 2007 Aug;14(8):754-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue.
  • OBJECTIVES: To assess the relationship between the tissue levels of pyrimidine nucleoside phosphorylase (PyNpase) and clinicopathological parameters in human bladder cancer and to investigate the PyNpase levels in rat and mouse urinary bladder initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN).
  • METHODS: The PyNpase levels in tumor tissue, normal tissue adjacent to the tumor, and normal tissue apart from the tumor were measured in 102 patients.
  • Additionally, the PyNpase levels were measured in rat and mouse urinary bladders treated with BBN.
  • RESULT: The PyNpase levels of tumor tissue significantly correlated to the tumor grade and growth pattern (papillary/non-papillary), while stage, multiplicity, and tumor shape (peduncle/sessile) were not independent factors.
  • The low-risk tumor of primary, single, G1-Ta showed significantly low levels of PyNpase.
  • The PyNpase levels in the tumor tissue were significantly higher than those in the normal tissue.
  • The PyNpase levels in rat bladder tissue were significantly higher in the BBN-treatment groups than in those in the control group, only during the early carcinogenic stage.
  • The PyNpase levels in mouse bladder tissue were significantly higher in BBN-treatment groups than in those in the control group during the whole experiment period.
  • CONCLUSION: Our results indicated that not only tumor tissue but also normal tissue adjacent to the tumor had a potential of angiogenesis for tumor development, and transurethral resection of the bladder tumor with a wide normal margin seems to be a reasonable strategy for decreasing the risk of recurrence.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Neoplasm Recurrence, Local / metabolism. Pentosyltransferases / metabolism. Thymidine Phosphorylase / metabolism. Urinary Bladder / enzymology. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Butylhydroxybutylnitrosamine. Carcinogens. Female. Humans. Male. Mice. Mice, Inbred C3H. Middle Aged. Neoplasm Invasiveness. Pyrimidine Phosphorylases. Rats. Rats, Inbred F344. Risk Factors. Species Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681069.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carcinogens; 3817-11-6 / Butylhydroxybutylnitrosamine; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.- / Pyrimidine Phosphorylases; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


74. Santos Arrontes D, Fernández Arjona M, Valer López-Fando MP, Pascual Mateo C, De Castro Barbosa F, Cortés Aránguez I, Jiménez I: [Tobacco consumption and bladder cancer mortality in Spain]. Arch Esp Urol; 2006 Mar;59(2):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tobacco consumption and bladder cancer mortality in Spain].
  • [Transliterated title] Consumo de tabaco y mortalidad por cáncer vesical en España.
  • OBJECTIVES: To establish the trend of the bladder cancer adjusted mortality and its correlation with tobacco consumption in different Spanish Autonomic Communities over a 15 year period.
  • METHODS: We evaluate the trends of mortality rates associated with bladder cancer between January 1st 1989 and December 31st 2002 in the geographic area of Spain, as well as the tendency of tobacco consumption.
  • We calculate the average number of cigarettes (1 package = 20 cigarettes) consumed per person; we also calculate bladder cancer adjusted mortality rates, presented as number of deaths for that cause per 100.000 persons year, and the ratio between number of packages of cigarettes consumed and adjusted mortality rate.
  • RESULTS: Mean adjusted bladder cancer mortality rate over the period of study was 9.4 deaths per 100.000 habitants year, and mean tobacco consumption was 109.7 packages per person year.
  • There has been a 2.05% yearly increase of bladder cancer associated mortality, mean cigarette consumption has diminished 1.3% per year.
  • The increase in the incidence of bladder cancer does not seem to be related with higher tobacco consumption currently, therefore it may be related with other genetic or environmental factors.
  • [MeSH-major] Smoking / adverse effects. Smoking / epidemiology. Urinary Bladder Neoplasms / mortality

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649519.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


75. Paick JS, Um JM, Kwak C, Kim SW, Ku JH: Influence of bladder contractility on short-term outcomes of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate. Urology; 2007 May;69(5):859-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of bladder contractility on short-term outcomes of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate.
  • OBJECTIVES: To determine the effect of bladder contractility on the outcomes of high-power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in men with lower urinary tract symptoms.
  • No differences were found in the change in the International Prostate Symptom Score or maximal flow rate according to age, prostate volume, or bladder outlet obstruction index.
  • The weak bladder contractility index (BCI) group (BCI less than 100) had a smaller decrease in the median International Prostate Symptom Score and a smaller increase in the maximal flow rate than did those in the higher BCI group (BCI of 100 or more; P = 0.047 and P = 0.035, respectively).
  • The baseline clinical parameters, including age, prostate volume, serum prostate-specific antigen, and bladder outlet obstruction index, were not significantly different between the low and greater BCI groups.
  • CONCLUSIONS: The results of the present study have shown that after high-power potassium-titanyl-phosphate laser vaporization, patients with weak bladder contractility had less subjective and objective improvement than did those patients with normal or strong bladder contractility.
  • [MeSH-major] Laser Therapy / methods. Muscle, Smooth / physiology. Prostatic Hyperplasia / surgery. Urinary Retention / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Follow-Up Studies. Humans. Male. Middle Aged. Muscle Contraction / physiology. Patient Satisfaction. Phosphates. Probability. Prospective Studies. Risk Assessment. Severity of Illness Index. Statistics, Nonparametric. Titanium. Treatment Outcome. Urinary Bladder / physiology. Urodynamics. Volatilization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482922.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphates; 12690-20-9 / potassium titanylphosphate; D1JT611TNE / Titanium
  •  go-up   go-down


76. Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ: Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg; 2005 Sep;92(9):1124-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique.
  • BACKGROUND: Bladder and sexual dysfunction are recognized complications of mesorectal resection.
  • METHODS: Bladder and sexual function were assessed in patients who had undergone laparoscopic rectal, open rectal or laparoscopic colonic resection as part of the UK Medical Research Council Conventional versus Laparoscopic-Assisted Surgery In Colorectal Cancer (CLASICC) trial, using the International Prostatic Symptom Score, the International Index of Erectile Function and the Female Sexual Function Index.
  • Sexual and bladder function data from the European Organization for Research and Treatment of Cancer QLQ-CR38 collected in the CLASICC trial were used for comparison.
  • Bladder function was similar after laparoscopic and open rectal operations for rectal cancer.
  • CONCLUSION: Laparoscopic rectal resection did not adversely affect bladder function, but there was a trend towards worse male sexual function.
  • [MeSH-major] Laparoscopy / adverse effects. Rectal Neoplasms / surgery. Sexual Dysfunction, Physiological / etiology. Urinary Bladder Diseases / etiology


77. Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, Sigala S, Carbone A: Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Clin Neuropharmacol; 2006 Jul-Aug;29(4):220-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
  • INTRODUCTION: Parkinson disease (PD) patients present urinary symptoms during the course of the disease, very often suggestive of overactive bladder and sustained by neurogenic detrusor overactivity.
  • These symptoms cause a severe lowering of quality of life determining social withdrawal and they need to be early diagnosed to restore social interaction and prevent urinary tract complications.
  • Today overactive bladder diagnosis is easier, thanks to the availability of new investigative tools, particularly voiding questionnaires.
  • The aim of the present study was to evaluate the reliability of the Overactive Bladder screener (OAB screener/OAB-questionnaire), a new voiding questionnaire specifically developed for the overactive bladder diagnosis in PD subjects suffering from overactive bladder symptoms.
  • The study suggests that this clinical tool might be used for neurogenic overactive bladder diagnosis and that it seems to be a useful outcome measure for treatments of neurogenic OAB.
  • [MeSH-major] Muscarinic Antagonists / therapeutic use. Parkinson Disease / physiopathology. Surveys and Questionnaires. Urinary Bladder, Neurogenic / diagnosis. Urinary Incontinence / diagnosis. Urodynamics

  • Genetic Alliance. consumer health - Parkinson Disease.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855424.001).
  • [ISSN] 0362-5664
  • [Journal-full-title] Clinical neuropharmacology
  • [ISO-abbreviation] Clin Neuropharmacol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Muscarinic Antagonists
  •  go-up   go-down


78. Ferreira Ede C, Matias JE, Campos AC, Tâmbara Filho R, Rocha LC, Timi JR, Sado HN, Sakamoto DG, Tolazzi AR, Soares Filho Mde P: [Surgical bladder wounds treated with Orbignya phalerata aqueous extract: controlled study in rats]. Acta Cir Bras; 2006;21 Suppl 3:33-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical bladder wounds treated with Orbignya phalerata aqueous extract: controlled study in rats].
  • [Transliterated title] Análise da cicatrização da bexiga com o uso do extrato aquoso da Orbignya phalerata (babaçu): estudo controlado em ratos.
  • PURPOSE: The aim of this paper is to analyse comparatively the histological alteration provided by the use of the aqueous extract of Orbignya phalerata, in the healing process of bladder surgical wounds.
  • The experimental procedure consisted of a longitudinal 2 cm long bladder incision and single layer interrupted suture of 5-0 polyglactine 910.
  • The Orbignya phalerata had a favoring healing effect in the surgical incision on rats bladder.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17293935.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] POR
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Plant Extracts
  •  go-up   go-down


79. Volpe A, Racioppi M, D'Agostino D, Cappa E, Filianoti A, Bassi PF: Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol; 2010 Jun;62(2):133-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C for the treatment of bladder cancer.
  • Bladder cancer is a heterogeneous disease: approximately 75% of its forms are non muscle invasive neoplasms.
  • Standard treatment for non muscle invasive bladder cancer (NMIBC) consists of complete transurethral resection (TURB) of all visible lesions.
  • The aim of the present paper is to review findings from the most relevant studies and evaluate the potentials of mitomycin C (MMC) in the treatment of non muscle invasive bladder cancer.
  • Studies were identified by searching MEDLINE(R) and Pubmed(R) databases up to 2010 using both medical subject heading (Mesh) and a free text strategy with the name of known individual chemotherapeutic drug and the following key words: "non muscle-invasive bladder cancer", "intravesical therapy", "Mitomycin C", "Device Therapy".
  • From literature is clear that in case of low or intermediate risk superficial bladder cancer, MMC is one of the most used agents with limited side effects.
  • MMC early istillation seems effective in preventing tumour recurrence in low risk non muscle invasive neoplasms.
  • MMC maintenance chemotherapy continue to be considered effective in reducing tumour recurrence rate in low and intermediate risk tumours.
  • It is known in literature that the lack of response to intravesical chemotherapy in patients with non muscle invasive bladder cancer is due to two factors: lack of sensitivity of the neoplasm to intravesical chemotherapy and inadequate drug delivery to the tumour.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Mitomycin / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Clinical Trials as Topic. Drug Eruptions / epidemiology. Humans. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20562793.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


80. Alvarez V, Lodillinsky C, Umerez S, Sandes E, Eiján AM: Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment. Int J Mol Med; 2005 Oct;16(4):565-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
  • Bacillus Calmette-Guérin (BCG) is considered to be one of the most effective treatments for superficial and in situ bladder cancer.
  • As nitric oxide (NO) has been detected in the bladder of BCG-treated patients, we analyzed the role of endogenous NO generated after BCG treatments on human (T24) and murine (MB49 and MBT2) bladder tumor cells in the viability of tumor and immune cells, both in vitro and in vivo.
  • Tumor histology with hematoxylin and eosin and Masson's trichrome staining was performed.
  • BCG induced a direct inhibition of tumor cell growth in vitro, independently of NO levels.
  • Besides, BCG-mediated NO production by tumor cells induced the death of spleen and peritoneal cells in syngeneic mice.
  • The in vivo inhibition of NO synthase (NOS) activity by NG-nitro-L-arginine methyl ester in combination with BCG, improved tumor regression by generating a healing tissue.
  • The in vivo inhibition of NO ameliorated immunotherapy with BCG by additional tumor growth inhibition.
  • Our results suggested the possibility that the final outcome of patients with bladder tumors may improve by modulating NOS activity concomitantly with BCG therapy.
  • [MeSH-major] BCG Vaccine / pharmacology. NG-Nitroarginine Methyl Ester / pharmacology. Nitric Oxide / antagonists & inhibitors. Urinary Bladder Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / drug effects. Drug Therapy, Combination. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Female. Humans. Injections, Intralesional. Macrophages, Peritoneal / cytology. Macrophages, Peritoneal / drug effects. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Neoplasms, Experimental / prevention & control. Nitric Oxide Synthase / metabolism. Nitric Oxide Synthase / pharmacology. Spleen / cytology. Spleen / drug effects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142388.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Enzyme Inhibitors; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  •  go-up   go-down


81. Herr HW, Donat SM, Reuter VE: Management of low grade papillary bladder tumors. J Urol; 2007 Oct;178(4 Pt 1):1201-5; discussion 1205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of low grade papillary bladder tumors.
  • PURPOSE: We evaluated the management and treatment outcomes of low grade papillary bladder tumors.
  • MATERIALS AND METHODS: We evaluated 215 patients diagnosed with low grade and noninvasive papillary bladder tumors, and followed them every 6 months with flexible cystoscopy for 6 to 10 or more years.
  • Tumor recurrence was treated with transurethral resection or outpatient cystoscopic fulguration.
  • With a median followup of 8 years tumor recurrences averaged 6.2 (range 1 to 19) requiring 0.34 transurethral resections per year or 1 transurethral resection every 3 years, or 0.61 fulgurations or 1 fulguration approximately every 2 years.
  • There were 17 patients (8%) who had progression in grade or stage and 1 patient (0.5%) died of bladder cancer.
  • Patients most likely to have recurrence had multiple tumors, low grade (TaLG) carcinoma or tumor at first followup cystoscopy.
  • CONCLUSIONS: Surveillance cystoscopy at 6-month intervals coupled with outpatient fulguration controls recurrent tumors and reduces the therapeutic burden for patients diagnosed with low grade papillary bladder tumors.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystoscopy. Papilloma / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Electrocoagulation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Reoperation. Survival Analysis. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2007 Oct;178(4 Pt 1):1146-7 [17698132.001]
  • [CommentIn] Nat Clin Pract Urol. 2008 Jun;5(6):294-5 [18446132.001]
  • (PMID = 17698090.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Gearhart JP, Baird AD: The failed complete repair of bladder exstrophy: insights and outcomes. J Urol; 2005 Oct;174(4 Pt 2):1669-72; discussion 1672-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The failed complete repair of bladder exstrophy: insights and outcomes.
  • Total dehiscence occurred in 6 males, major bladder prolapse in 3, minor prolapse in 3, pubic separation in 1, impassable stricture in 1, and total hemiglans and corporal loss in 2.
  • One patient with pubic separation and urethral and skin loss underwent re-closure with osteotomy, C-R repair after skin expanders and later bladder neck repair.
  • Two females underwent re-closure with osteotomy and urethral replacement with tubularized bladder.
  • [MeSH-major] Bladder Exstrophy / surgery. Postoperative Complications / surgery. Reconstructive Surgical Procedures / methods. Urologic Surgical Procedures / methods


83. Naim M: Immature embryoid teratoma of the gall bladder: case of a primary primitive neoplasm. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immature embryoid teratoma of the gall bladder: case of a primary primitive neoplasm.
  • This study presents diagnostic histopathological features of a primary embryoid teratomatous neoplasm in the gall bladder of a 60-year-old woman, and also discusses its pathogenesis.
  • The residual endothelial lining of the gall bladder showed in situ and proliferative changes characteristic of an endodermal tumour.
  • Results show that the mature adult gall bladder is susceptible to primary neoplasms of a primitive nature ranging from immature embryoma and teratoma to neuroectodermal tumour.
  • Such primitive neoplasms in adult organs where benign neuroectodermal elements are present may evolve from a constituent cell of an adult organ acquired during embryogenesis from a morula that differentiated into trophoblastic (outer) and embryoblastic (inner) cells, and existing dormant cells at rest until reactivation during oncogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Apr;16(4):299-308 [12692194.001]
  • [Cites] Br J Surg. 1961 Jul;49:3-8 [14492775.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]
  • [Cites] J Postgrad Med. 2006 Oct-Dec;52(4):304-5 [17102555.001]
  • [Cites] J Pediatr Surg. 2007 Oct;42(10):E25-7 [17923185.001]
  • (PMID = 21687015.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027538
  •  go-up   go-down


84. Fornari D, Steven K, Hansen AB, Jepsen JV, Poulsen AL, Vibits H, Horn T: Transitional cell bladder tumor: predicting recurrence and progression by analysis of microsatellite loss of heterozygosity in urine sediment and tumor tissue. Cancer Genet Cytogenet; 2006 May;167(1):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell bladder tumor: predicting recurrence and progression by analysis of microsatellite loss of heterozygosity in urine sediment and tumor tissue.
  • Transitional cell bladder tumors (TCT) is prone to recurrence (60-80%) after tumor resection.
  • This analysis was performed on the urine sediment and tumor tissue from 59 patients with bladder TCT and on the urine and normal-looking mucosa from 25 patients with a history of bladder TCT but no evidence of disease at the time of the study inclusion.
  • The median follow-up period was 23.1 months (range, 2-48 months) for the 59 patients with bladder TCT and 25 months (range, 4-57 months) for the 25 patients without evidence of ongoing active disease.
  • In patients with noninvasive TCT, correlation between 11p tumor tissue LOH and recurrence was found.
  • Similarly, 8p LOH in both urine sediment and tumor tissue correlated with progression.
  • Finally, in the group of patients with a history of bladder TCT, normal tissue 8p and/or 11p LOH correlated with recurrence.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Loss of Heterozygosity. Microsatellite Repeats. Neoplasm Recurrence, Local / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. DNA, Neoplasm / urine. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682280.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


85. Spilde NL: A journey to continence: a case study of overactive bladder syndrome. Urol Nurs; 2008 Jun;28(3):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A journey to continence: a case study of overactive bladder syndrome.
  • Overactive bladder is a problem that many women experience and suffer with in silence for years.
  • This article presents the story of her journey and perseverance to achieve control of her bladder.
  • [MeSH-major] Urinary Bladder, Overactive / prevention & control

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18605514.001).
  • [ISSN] 1053-816X
  • [Journal-full-title] Urologic nursing
  • [ISO-abbreviation] Urol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzofurans; 0 / Muscarinic Antagonists; 0 / Pyrrolidines; APG9819VLM / darifenacin
  • [Number-of-references] 14
  •  go-up   go-down


86. Nakane K, Katoh T, Yokoi S, Ehara H, Takahashi Y, Ishihara S, Deguchi T: [Recurrence of bladder cancer in fossa navicularis 17 months after cystourethrectomy: a case report]. Hinyokika Kiyo; 2005 Sep;51(9):631-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence of bladder cancer in fossa navicularis 17 months after cystourethrectomy: a case report].
  • We report a case of bladder cancer recurrence in fossa navicularis of urethra 17 months after cystourethrectomy for bladder cancer.
  • A 75-year-old man had undergone cystourethrectomy preserving between fossa navicularis and external meatus, and ileal conduit urinary diversion for advanced bladder cancer on June 24, 2002.
  • Endoscopic examination of the residual urethra showed multiple, papillary sessile tumors which almost filled the fossa navicularis.
  • Histopathological findings showed urothelial carcinoma pTa, G2>G3, which was identical to primary tumor.
  • Tumor had not invaded the corpus cavernosum.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Cystectomy. Urethra / surgery. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Penis / surgery. Postoperative Period. Urinary Diversion

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229378.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • Repeat staging CT of the abdomen and pelvis confirmed tumor recurrence in the left pelvis.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pain / radiotherapy. Palliative Care / methods. Urinary Bladder Neoplasms / radiotherapy


88. Alexandroff AB, Nicholson S, Patel PM, Jackson AM: Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy; 2010 Jul;2(4):551-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
  • Today, bacillus Calmette-Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that is arguably superior to intravesical chemotherapy for superficial disease and is commonly used as the first-line adjuvant treatment.
  • Much has been learnt about the effects of BCG on bladder cancer and the immune system, but deeper understanding is required in order to improve its efficacy further, to be able to reliably predict responders and ultimately to adapt this most successful form of cancer immunotherapy for the treatment of other malignancies.
  • [MeSH-major] BCG Vaccine / therapeutic use. Cancer Vaccines / immunology. Immunotherapy. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20636008.001).
  • [ISSN] 1750-7448
  • [Journal-full-title] Immunotherapy
  • [ISO-abbreviation] Immunotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Cancer Vaccines
  •  go-up   go-down


89. Liu YL, Wen FQ, Sun F: [Functional bladder capacity in 1,500 children with nocturnal enuresis]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr;10(2):170-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional bladder capacity in 1,500 children with nocturnal enuresis].
  • OBJECTIVE: To study the association of functional bladder capacity with the severity of bedwetting in children with nocturnal enuresis.
  • METHODS: A questionnaire investigation was performed in 1 500 children with nocturnal enuresis and the functional bladder capacity was examined by B-ultrasound.
  • Six hundred and thirty-seven patients (42.4%) showed a decreased functional bladder capacity (less than 50% of normal level).
  • The incidence of the reduction in functional bladder capacity in the above four groups was 79.2%, 48.3%, 29.7% and 14.3% respectively and a significant difference was noted among the four groups.
  • CONCLUSIONS: Most of children with nocturnal enuresis showed decreased functional bladder capacity.
  • Functional bladder capacity is associated with the severity of bedwetting in children with nocturnal enuresis.
  • [MeSH-major] Nocturnal Enuresis / physiopathology. Urinary Bladder / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433540.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Ozkan B, Demirkesen O, Durak H, Uygun N, Ismailoglu V, Cetinel B: Which factors predict upper urinary tract deterioration in overactive neurogenic bladder dysfunction? Urology; 2005 Jul;66(1):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which factors predict upper urinary tract deterioration in overactive neurogenic bladder dysfunction?
  • OBJECTIVES: To determine whether bladder histopathologic changes, detrusor leak point pressure (DLPP), disease duration, and preoperative catheterization time can predict for upper urinary tract (UUT) deterioration in patients with overactive neurogenic bladder dysfunction (ONBD).
  • The patients had undergone perioperative full-thickness bladder biopsies during augmentation cystoplasty.
  • [MeSH-major] Urinary Bladder, Neurogenic / complications. Urinary Incontinence / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Kidney Diseases / etiology. Male. Middle Aged. Risk Factors. Time Factors. Ureteral Diseases / etiology. Urinary Catheterization

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15992868.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Abrams P, Andersson KE: Muscarinic receptor antagonists for overactive bladder. BJU Int; 2007 Nov;100(5):987-1006
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscarinic receptor antagonists for overactive bladder.
  • Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia.
  • Bladder outlet obstruction can be a contributing factor in DO, possibly through cholinergic denervation of the detrusor and supersensitivity of muscarinic receptors to acetylcholine, although the prevalence of OAB is similar in men and women across age groups.
  • Acetylcholine is the primary contractile neurotransmitter in the human detrusor, and antimuscarinics exert their effects on OAB/DO by inhibiting the binding of acetylcholine at muscarinic receptors M(2) and M(3) on detrusor smooth muscle cells and other structures within the bladder wall.
  • Antimuscarinics are generally well tolerated, even in special populations (e.g. men with bladder outlet obstruction, elderly patients, children).
  • Development of an antimuscarinic with functional selectivity for the bladder would reduce the occurrence of antimuscarinic adverse events.
  • [MeSH-major] Muscarinic Antagonists / therapeutic use. Receptors, Muscarinic / drug effects. Urinary Bladder, Overactive / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922784.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Receptors, Muscarinic
  • [Number-of-references] 212
  •  go-up   go-down


92. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, Czerniak B: Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest; 2005 Apr;85(4):532-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways.
  • Bladder cancer develops in the urothelial lining from intraurothelial preneoplasia via two pathways, papillary and nonpapillary, which correspond to nonaggressive and aggressive forms of the disease.
  • Because these two forms of cancer may develop via distinct molecular events, we examined the gene expression patterns in the development of bladder cancer from preneoplasia along papillary and nonpapillary pathways.
  • The expression profiles of 19 pairs of RNA samples from adjacent urothelium and tumors were analyzed using cDNA microarrays.
  • For selected genes their expressions were verified on a cohort of 251 bladder cancer patients using tissue microarray and immunohistochemistry and were related to clinicopathological parameters including follow-up data.
  • Tumors characterized by the low expression of e-cadherin and the high expression of DNA alpha-topoisomerase II had a high propensity for distant metastasis and were associated with poor survival.
  • [MeSH-major] Multigene Family. Transcription, Genetic. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778693.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA91846; United States / NCI NIH HHS / CA / U01 CA066723; United States / NCI NIH HHS / CA / U01 CA85078
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary
  •  go-up   go-down


93. Varela JC, Atkinson C, Woolson R, Keane TE, Tomlinson S: Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer; 2008 Sep 15;123(6):1357-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.
  • We investigated complement inhibitor expression in bladder cancer and examined the hypothesis that selective pressure of an antibody response (anti-MUC1) results in the upregulated expression of complement inhibitors on tumor cells.
  • Paired samples of tumor and normal tissue from 22 bladder cancer patients were analyzed for expression of MUC1, CD46, CD55 and CD59, and matched serum samples analyzed for anti-MUC1 IgM and IgG levels.
  • MUC1 mRNA was upregulated in 86% of tumor samples.
  • CD46 was upregulated in 77%, CD55 in 55% and CD59 in 59% of tumors.
  • Low titer anti-MUC1 IgM was detected in normal human sera, but was elevated in 41% of the bladder cancer patients.
  • In conclusion, the data demonstrate upregulated complement inhibitor expression and the presence of an anti-MUC1 antibody response in bladder cancer patients and support the hypothesis of antibody-mediated immune selection.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(2):213-9 [7532466.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):129-42 [8686736.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1325-31 [8869094.001]
  • [Cites] Int J Cancer. 1997 Jan 6;70(1):14-25 [8985085.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1455-67 [9358772.001]
  • [Cites] J Gastroenterol. 1998 Jun;33(3):354-61 [9658314.001]
  • [Cites] Cancer Immunol Immunother. 1998 Jul;46(5):245-52 [9690452.001]
  • [Cites] Immunol Today. 1999 Dec;20(12):576-82 [10562709.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):574-83 [10653872.001]
  • [Cites] APMIS. 1998 Sep;106(9):869-78 [9808413.001]
  • [Cites] Cancer Immunol Immunother. 1999 Jan;47(5):272-7 [10022471.001]
  • [Cites] Cancer Immunol Immunother. 1999 Apr;48(1):47-55 [10235488.001]
  • [Cites] BJU Int. 1999 Aug;84(3):350-2 [10468735.001]
  • [Cites] Cancer Immunol Immunother. 2005 Mar;54(3):254-64 [15372205.001]
  • [Cites] J Exp Med. 2005 Feb 21;201(4):567-77 [15710649.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1523-30 [15883171.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10562-8 [16288049.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7098-102 [16301611.001]
  • [Cites] Urology. 2005 Dec;66(6):1321-6 [16360477.001]
  • [Cites] Trends Immunol. 2006 Feb;27(2):102-8 [16406700.001]
  • [Cites] J Oral Pathol Med. 2006 Oct;35(9):560-7 [16968237.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):9-18 [17170757.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):231-9 [17234541.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):3178-86 [17709533.001]
  • [Cites] J Immunol. 2007 Nov 1;179(9):5793-802 [17947652.001]
  • [Cites] J Autoimmun. 2007 Dec;29(4):295-302 [17826951.001]
  • [Cites] J Autoimmun. 2007 Dec;29(4):287-94 [17826952.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] Gynecol Oncol. 2000 Feb;76(2):176-82 [10637067.001]
  • [Cites] Eur J Haematol. 2000 Jan;64(1):3-9 [10680700.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):80-6 [11139317.001]
  • [Cites] Histopathology. 2002 Apr;40(4):339-47 [11943018.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):97-100 [12455059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):388-92 [12540904.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):930-6 [14712499.001]
  • [Cites] Adv Immunol. 2004;82:249-93 [14975259.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jun;19(6):643-7 [15151618.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1673-80 [2258699.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):368-73 [1384649.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2457-9 [8495404.001]
  • [Cites] Br J Cancer. 1993 Nov;68(5):926-31 [7692919.001]
  • [Cites] Br J Urol. 1994 Mar;73(3):256-62 [8162502.001]
  • (PMID = 18561323.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104579-02; United States / NCI NIH HHS / CA / R21 CA104579; United States / NCI NIH HHS / CA / R21 CA 104579; United States / NCI NIH HHS / CA / R21 CA104579-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD46; 0 / Antigens, CD55; 0 / Antigens, CD59; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger; 9007-36-7 / Complement System Proteins
  • [Other-IDs] NLM/ NIHMS108939; NLM/ PMC2681224
  •  go-up   go-down


94. Capozza N, Torino G, Collura G, Battaglia S, Guzzo I, Caione P, Dello Strologo L: Renal transplantation in patients with "valve bladder": is bladder augmentation necessary? Transplant Proc; 2010 May;42(4):1069-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal transplantation in patients with "valve bladder": is bladder augmentation necessary?
  • This disorder often results in small bladder and low compliance, which frequently requires bladder augmentation.
  • Herein, we report our experience in 5 children with "valve bladder" who underwent renal transplantation without preliminary bladder enlargement.
  • MATERIALS AND METHODS: Thirteen children with valve bladder undergoing renal transplantation were considered candidates for bladder augmentation.
  • In 8 children, bladder augmentation was performed before renal transplantation; in the remaining 5, the decision was postponed until after transplantation.
  • Periodically, renal function, bladder capacity, and compliance were assessed, and renal ultrasonography was performed.
  • RESULTS: At 1-, 2-, 4-, and 6-month follow-up, the 5 children who did not undergo bladder augmentation demonstrated normal renal function, with improved bladder capacity and absence of hydronephrosis.
  • No significant difference was evident between the 2 groups (augmented vs nonaugmented) insofar as renal function, bladder capacity, or hydronephrosis.
  • After transplantation, bladder augmentation was not deemed necessary in any of the 5 children because of complete restoration of clinical and urodynamic parameters.
  • CONCLUSION: Renal transplantation can be performed safely without preemptive bladder augmentation.
  • The decision about the need for bladder augmentation should be made only after normal diuresis is restored.
  • [MeSH-major] Kidney Transplantation / physiology. Urinary Bladder / anatomy & histology. Urinary Bladder Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Anuria / surgery. Child. Child, Preschool. Creatinine / blood. Diuresis / physiology. Humans. Kidney Function Tests. Oliguria / surgery. Treatment Outcome. Ureter / surgery. Ureter / transplantation. Urinary Tract / abnormalities

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534225.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


95. Ke QS, Kuo HC: Transurethral incision of the bladder neck to treat bladder neck dysfunction and voiding dysfunction in patients with high-level spinal cord injuries. Neurourol Urodyn; 2010 Jun;29(5):748-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral incision of the bladder neck to treat bladder neck dysfunction and voiding dysfunction in patients with high-level spinal cord injuries.
  • PURPOSE: Detrusor-sphincter dyssynergia (DSD) and bladder neck dysfunction (BND) may cause voiding dysfunction in patients with spinal cord injury (SCI).
  • We report the surgical outcomes in patients with high-level SCI who underwent transurethral incision of the bladder neck (TUI-BN).
  • TUI-BN also leads to improvement in reducing bladder outlet resistance, reduction in occurrence of AD episodes, and improvement in QoL.
  • [MeSH-major] Spinal Cord Injuries / complications. Urinary Bladder / surgery. Urinary Bladder Diseases / etiology. Urinary Bladder Diseases / surgery. Urination Disorders / etiology. Urination Disorders / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 19731313.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Mahnken A, Kausch I, Feller AC, Krüger S: E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep; 2005 Oct;14(4):1065-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
  • Abnormal (i.e., lost or decreased) expression of E-cadherin has been linked to invasiveness of many malignant tumors, including bladder carcinomas.
  • To our knowledge, studies analyzing the prognostic impact of E-cadherin immunoreactivity especially in minimally invasive transitional cell bladder carcinomas (stage pT1) have not been published in the Anglo-American literature.
  • In the present study, we immunostained 69 cases of pT1 transitional cell bladder carcinomas for E-cadherin using multitissue arrays.
  • By univariate Cox regression analysis, abnormal E-cadherin immunostaining correlated significantly (p=0.005) with early tumor recurrence, but not with early tumor progression (p=0.168).
  • In a multivariate analysis, this parameter was identified, besides tumor grade (p=0.002), as an independent predictor of recurrence-free survival (p=0.016).
  • Concerning tumor progression, age was identified as the single independent prognostic parameter (p=0.041), but E-cadherin immunoreactivity displayed a tendentious independent predictive value in this respect (p=0.071).
  • We conclude from our data that immunohistochemical E-cadherin staining may provide additional prognostic information in patients with pT1 bladder carcinomas.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cadherins / biosynthesis. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cohort Studies. Cytoplasm / metabolism. Disease Progression. Disease-Free Survival. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Recurrence. Time Factors. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142373.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


97. Wang D, Wang Z, Tian B, Li X, Li S, Tian Y: Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol; 2008 May;15(5):435-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs.
  • OBJECTIVES: To investigate the inhibitory effect of sodium butyrate (NaB) on the proliferation of human bladder cancer cell lines and its synergetic effect with anticancer drugs in treating bladder cancer in vitro and in vivo.
  • METHODS: The inhibitory effects of NaB on human bladder cancer cell lines in vitro and the synergetic effect of NaB with mitomycin c, cisplatin (CDDP) and adriamycin were detected by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay.
  • In vivo synergetic effects were detected in N-methyl-N-nitrosourea induced bladder cancer model rats.
  • RESULTS: NaB significantly inhibited the growth of bladder cancer cell lines in a concentration and time dependent manner.
  • Better results of tumor inhibition have been achieved when NaB was combined with CDDP, mitomycin c and adriamycin, rather than used alone.
  • Furthermore, 2 h exposure to NaB can sensitize bladder cancer to chemotherapy agents.
  • The Bcl-2 expression in bladder cancer cells is decreased and caspase-3 expression increased after NaB treatment.
  • Intravesical application of NaB combined with CDDP can significantly inhibit tumor growth and progression.
  • 2 h expose to NaB can also sensitize bladder cancer to anticancer drugs.
  • NaB may be an excellent candidate agent for intravesical application in treating bladder cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Butyrates / pharmacology. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Mitomycin / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Synergism. Female. Humans. Rats. Rats, Wistar. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452462.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Butyrates; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


98. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT: Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res; 2005 Aug 15;65(16):7081-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.
  • In the United States each year, almost 13,000 deaths are attributable to bladder cancer, with the majority of these deaths related to higher stage, muscle-invasive solid tumors.
  • Identifying alterations in this pathway in bladder cancer may prove useful for defining the invasive phenotype and provide targets for guiding therapy.
  • Using a population-based study of bladder cancer (n = 355), we examined epigenetic alterations, specifically gene promoter hypermethylation, of four SFRP genes in addition to immunohistochemical staining of TP53, which has been previously shown to be a predictor of invasive disease.
  • Both TP53 alteration and SFRP gene methylation showed significant independent associations with invasive bladder cancer.
  • Classifying tumors based on SFRP methylation status and TP53 protein staining intensity may be a clinically powerful predictor of invasive, deadly disease.
  • [MeSH-major] Epigenesis, Genetic. Gene Silencing. Membrane Proteins / genetics. Proteins / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Protein p53 / biosynthesis. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Invasiveness. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103055.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES00002; United States / NIEHS NIH HHS / ES / P42ES005947; United States / NIEHS NIH HHS / ES / P42ES007373; United States / NCI NIH HHS / CA / R01 CA100679; United States / NIEHS NIH HHS / ES / T32 ES007155
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP2 protein, human; 0 / SFRP4 protein, human; 0 / Tumor Suppressor Protein p53; 0 / frizzled related protein-1
  •  go-up   go-down


99. Shirakawa H, Kozakai N, Sugiura H, Hara S: [Prostatic retention cyst around the bladder neck: a case report]. Hinyokika Kiyo; 2009 Sep;55(9):583-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic retention cyst around the bladder neck: a case report].
  • We report a case of a prostatic retention cyst around the bladder neck causing prostatitis-like symptoms.
  • Blood examination and urinalysis showed neither systemic inflammation nor urinary tract infection.
  • Transrectal ultrasonography (TRUS), magnetic resonance imaging (MRI) and cystoscope revealed a projecting prostatic cyst which occupied the bladder outlet and seemed to cause the prostatitis-like symptoms.
  • [MeSH-major] Cysts / diagnosis. Prostatic Diseases / diagnosis. Urinary Bladder

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827624.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Wiygul J, Palmer LS: Spontaneous bladder perforation in a neonate. Urology; 2010 Jul;76(1):164-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous bladder perforation in a neonate.
  • Spontaneous bladder perforation in the newborn setting is a rare clinical phenomenon that can be life threatening if left untreated.
  • Several risk factors have been identified in previously reported cases such as hypoxia and bladder diverticula.
  • We present the first case of neonatal bladder rupture without any identifiable risk factors.
  • [MeSH-major] Urinary Bladder Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20363492.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement